

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ :		(11) International Publication Number: WO 99/43795	
C12N 15/00, A01K 67/027, C12N 15/86, 9/72		A1	(43) International Publication Date: 2 September 1999 (02.09.99)
(21) International Application Number: PCT/CA98/00607		(74) Agents: ERRATT, Judy, A. et al.; Gowling, Strathy & Henderson, Suite 2600, 160 Elgin Street, Ottawa, Ontario K1P 1C3 (CA).	
(22) International Filing Date: 25 June 1998 (25.06.98)		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 2,224,108 24 February 1998 (24.02.98) CA		Published With international search report.	
(71) Applicant (for all designated States except US): HER MAJESTY IN RIGHT OF CANADA as represented by THE MINISTER OF AGRICULTURE AND AGRI-FOOD CANADA [CA/CA]; Building 34, Centre for Food and Animal Research, Central Experimental Farm, Ottawa, Ontario K1A 0C6 (CA).			
(72) Inventors; and			
(75) Inventors/Applicants (for US only): GAVORA, Jan, S. [CA/CA]; 51 Forest Hill Avenue, Ottawa, Ontario K2C 1P7 (CA). FALCONER, Marcia, M. [CA/CA]; 33 Abingdon Drive, Nepean, Ontario K2H 7M5 (CA). NGUYEN, Thuy, H. [CA/CA]; Apartment 1201, 1316 Carling Avenue, Ottawa, Ontario K1Z 7L1 (CA). BENKEL, Bernhard, F. [CA/CA]; 293 Summit Avenue, Ottawa, Ontario K1H 5Z7 (CA).			

(54) Title: TRANS-SOMATICS WITH GENE TRANSFER INTO MAMMARY EPITHELIAL CELLS



(57) Abstract

A method is described to transfer a gene encoding a valuable compound, such as a pharmaceutical, into the secretory cells of the mammary gland to produce a new compound into the milk or to alter the composition of the milk. In this method the packaging cell line producing the viral-derived particles is infused into the mammary gland. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles to trans-infect the maximum number of mammary epithelial cells. After a period of time in the mammary gland, both the particles and the packaging cells will be destroyed by natural mechanisms while the trans-infected mammary epithelial cells continue to express gene(s) encoding the valuable compound or gene(s) to alter the composition of the milk. One or more genes can be trans-infected including DNA sequences that contribute to the efficient production of an active compound or to its stability. The packaging cells and the viral-derived particles used in this method can be those which trans-infect dividing or non-dividing cells and can be used either singly or together. This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GR	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	R	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

TRANS-SOMATICS WITH GENE TRANSFER INTO MAMMARY EPITHELIAL CELLS

5

FIELD OF INVENTION

The present invention relates to a method of producing value-added milk by the incorporation of specific DNA sequence(s) into the cells of the mammary gland. The term "value-added milk" is meant to mean milk containing a valuable compound, 10 such as a pharmaceutical, as well as milk with a changed composition so that the market value of the milk is enhanced.

BACKGROUND OF THE INVENTION

This invention is based upon a technique to transfer a gene, and related non-translated control sequences, into the secretory cells of the mammary gland to produce 15 new compounds in milk and/or to alter the milk composition.

An example of a compound produced into milk by this method would be a pharmaceutical which cannot be manufactured in a biologically active state. This 20 invention provides an alternative method of producing such pharmaceuticals into milk using the synthetic capabilities of the mammary epithelial cell.

Mammals produce copious amounts of complex proteins into milk to provide nutrition for their young. To harness this capability, the DNA of, for example a 25 valuable pharmaceutical, can be inserted into a mammary epithelial cell and this cell then will produce the active, pharmaceutical compound into the secreted milk. In a cow, the udder will act as a receptacle to hold the milk until it can be collected. The milk containing the added compound can be processed to extract and purify this pharmaceutical compound for subsequent sale, possibly to the medical and/or 30 veterinary communities, or the milk could be consumed directly as a therapeutic

agent.

At present there are two basic techniques that can be used to produce value-added milk. The first is to create a transgenic animal by microinjection or transfection of foreign DNA into an ovum or a fertilized egg. Incorporation of DNA at this stage in development generally results in a transgenic animal which carries the inserted DNA in every cell.

There are positive and negative aspects of producing a transgenic animal which expresses foreign proteins in its milk. A positive point is that a single founder animal can create a population of transgenic animals by natural reproduction. However, progenies do not always produce the exogenous protein at the same level as the original animal. Negative aspects include the technically difficult procedures required to produce the animal and the long time between adding the foreign DNA and harvesting the exogenous protein. In addition, the presence of even very small amounts of an active pharmaceutical in every tissue may be detrimental to the health of the animal.

An alternative method is to produce value-added milk by adding the desired DNA only to the cells of the mammary gland of the animal. This results in a **trans-somatic animal** (or chimera) which contains the inserted DNA essentially in only one tissue, the mammary gland.

Trans-somatic animals have the advantage that they can be produced with less technical difficulty. They also can be produced quickly so that there is a period of only weeks to months between adding the foreign DNA and harvesting the exogenous protein. Moreover, since only one tissue contains the added DNA and produces the resulting compound, health risks to the trans-somatic animal are reduced. Although the DNA is not passed on to the progeny, this is compensated for by the ease and speed with which a trans-somatic animal can be produced.

A trans-somatic goat which expresses human growth hormone (hGH) into milk has been produced by Archer et al. (1994). In Archer the viral-derived particles were infused into the mammary gland for approximately every two days for two weeks. The levels of the compound, human growth hormone, which was used as an 5 example, were very low and approached background levels after the first day. Also Gould et al. (United States Patent 5,215,904) described a method for increasing the rate of mitosis of mammary epithelial cells and then exposing these cells to viral particles for integration of the desired DNA into the epithelial cell.

10 To produce either a trans-somatic or a transgenic animal, exogenous DNA must pass through the exterior cell membrane. Eukaryotic cells have evolved a membrane which is impervious to most substances including heterologous DNA. Numerous techniques have been developed to bypass this barrier. These include:

15 electroporation,
carrier lipids (liposomes, negative, positive or neutral charged vesicles),
mechanical wounding of cells including microinjection, liquid or air-jet pressure and scrape loading,
use of particles composed partially or wholly of viral proteins.

20 Methods which have successfully produced trans-somatic animals include:

1) Arterial injection of DNA carried in liposomes (small lipid vesicles) was used to produce a trans-somatic mouse (Thierry et al. 1995). This technique can be adapted to deliver DNA to the mammary gland by injection into the major artery 25 serving the mammary gland but circulation of the blood carrying the DNA can result in transfection of multiple tissues.

2) Direct injection of the DNA into tissues was used successfully to add foreign DNA to muscle and other tissues (Furth et al. 1992). This technique can be adapted to inject virus-like particles, carrying the foreign DNA, directly into the tissue 30 of the udder.

3) Use of viral-derived particles carrying DNA coding for human growth

hormone (hGH) were infused through the teat canal, for example by Archer et al. (1994). This resulted in production of trans-somatic goats which expressed hGH into the milk.

5 Viruses reproduce within cells and therefore have evolved a technique to bypass the protective cell membrane to deliver the viral genome (DNA) into a host cell. To enter a cell, protein(s) of the outer viral shells first bind to receptors on the cell surface and then the virus is internalized.

10 The method used by Archer involves transfecting a cell line with DNA coding for various, but not all, proteins of a virus. This cell line, called a "packaging cell line", will produce empty virus shells which can bind to receptors on the host cell membrane. When heterologous DNA, coding for a pharmaceutical or other milk modification, is transfected into the packaging cell line, this DNA will be packaged
15 into the viral-derived particle. When the viral-derived particle comes in contact with a milk-producing cell, the viral proteins of the shell ensure that the heterologous DNA is carried into the cell. Other viral proteins, associated with the particle, integrate the heterologous DNA into the genome of the host cell so that the protein encoded by the DNA can be expressed. In this method the viral-derived particles are used to
20 introduce the heterologous DNA into the mammary gland.

25 The trans-somatic methods of the prior art offer advantages over the transgenic method; however the very low levels of foreign protein in the milk of the trans-somatic animal have limited the commercial success of these methods.

Thus the present invention is directed to methods of improving the yield of the foreign protein in the milk of a trans-somatic animal.

SUMMARY OF THE INVENTION

30 The present invention relates to a method of producing valuable compounds into milk and/or changing the composition of milk so as to enhance its properties

and/or its marketability. More specifically the present invention relates to the addition of specific DNA sequences, including non-translated regulatory sequences, to the cells of the mammary gland and the subsequent expression of compound(s) encoded by that DNA into the milk. Other DNA sequences that enhance the efficiency of production of the compound, enhance the stability of the compound, or result in biological activity of the compound can also be added to the mammary epithelial cells either at the same time or at a different time.

The novel method of the present invention involves the use of viral-derived particles and packaging cells which produce these particles for infusion into the mammary gland through the teat canal. The packaging cells will attach and survive for a period of time within the mammary gland. While the cells are viable, they will supply a continuous source of viral-derived particles. These viral-derived particles trans-infect only dividing cells and are destroyed relatively quickly in the mammary gland. Thus a continuous supply of viral-derived particles from the packaging cells present in the mammary gland will ensure that viral-derived particles are present and can trans-infect the mammary epithelial cells whenever they divide.

The packaging cells and viral-derived particles can be from retroviruses and from non-retroviruses. Most retroviral-derived particles trans-infect only dividing cells. Non-retroviral particles such as those from adenovirus, Epstein-Barr virus, or other viruses trans-infect non-dividing cells. Thus a mixture of the two types of particles, and the associated packaging cells if needed, will ensure delivery of the packaged DNA to the maximum number of cells. Moreover, DNA can be packaged into viral-derived particles *in vitro* and these can be used for trans-infection as well.

This method can be used alone or in combination with other novel methods designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells. Increasing the trans-infection of the mammary epithelial cells with the viral particles will result in a higher concentration of the valuable compound in the milk along with possible other compounds produced from

the inserted DNA that will enhance the efficient production, stability or activity of the compound.

Thus according to the present invention there is provided a method of
5 producing a trans-somatic mammal, wherein said method provides the incorporation
of a DNA sequence into the secretory cells of the mammary gland to alter the
composition of the milk, comprising the steps of: providing a vector containing a
DNA sequence encoding a valuable compound; packaging said vector into a cell line;
preparing a solution comprising the packaged vector and cell line producing said
10 packaged vector; and delivering said solution into the mammary gland to allow the
incorporation of the DNA into the secretory cells of the mammary gland.

BRIEF DESCRIPTION OF THE DRAWINGS

These and other features of the invention will become more apparent from the
15 following description in which reference is made to the appended drawings wherein:
FIGURE 1 shows the presence of amylase in an udder infused with Clone 10 (left
hind quarter) and Clone 12 (right hind quarter). The left front quarter was left
untouched as a negative control and the right front quarter was infused with DMEM
and Polybrene but no cells, to serve as a further negative control. Lanes 1, 2 & 3, early
20 premilk from 3 quarters of cow #99. Lane 1, control quarter (RF-); Lane 2, treated
quarter (RH+); Lane 3, treated quarter (LH+). Lanes 4, 5 & 6, late premilk from cow
#99. Lane 4, treated quarter (LH+); Lane 5, treated quarter (RH+); Lane 6, control
quarter (RH-). Lane 7, mixture of pig and chicken amylase standards; Lane 8, chicken
amylase standard.
25 **FIGURE 2** is a Western blot showing the presence of tPA in an udder infused with
Clone 1. Lane 1, premilk from treated quarter (LH+) of cow #56; Lane 2, premilk
from control quarter (LF-) of cow #56; Lane 3, premilk from treated quarter (RF+) of
cow #90.

30 DESCRIPTION OF THE PREFERRED EMBODIMENT

The present invention relates to a method to transfer a gene or genes, and

related non-translated control sequences into the secretory cells of a mammary gland to produce "value-added milk". The term "value-added milk" is meant to mean milk containing a valuable compound, such as a pharmaceutical, as well as milk with a changed composition so that the market value of the milk is enhanced.

5

Pharmaceuticals according to the present invention can include, but are not limited to: a tissue plasminogen activator, a blood clotting factor, an antibody, a protein to aid in weight reduction, a galactosyltransferase, a growth factor, an oncoprotein, a protease inhibitor, a hormone, a milk protein, a hormone receptor, a 10 tumor suppressor protein, an aging inhibitor, or an erythropoietin.

According to the present invention there is provided a suitable DNA vector (plasmid) containing the desired DNA sequence encoding the heterologous protein (valuable compound) and associated regulatory sequences such as promoters, 15 enhancers, introns, signal sequences, etc. Other sequences to produce compounds that increase efficient production, enhanced stability or are involved in biological activity of the compound can be included in the same or another DNA vector.

20 In one embodiment the vector is based on the pLXSN, pLNCX, or pLNSX plasmids provided under license from Fred Hutchinson Cancer Research Center.

According to the present invention the delivery of the DNA to the cells of the mammary gland is accomplished by the use of viral-derived particles and packaging cells, which produce these particles, for infusion into the mammary gland through the 25 teat canal. This infusion is a standard veterinary practice and usually involves the use of a cannula for insertion into the teat canal, the cannula being attached to a syringe containing a solution of the packaging cells and viral-derived particles.

It has already been established that such particles derived from retrovirus 30 trans-infect only dividing cells. Thus, the infusion of the particles and the packaging cells takes place when mammary cell division is naturally at a high level. In the

present invention heifers at 5 to 7 months pregnancy were used. It would also be possible to use non-pregnant mammals treated with hormones to induce mammary cell division and lactation prior to particle and cell infusion. However, this method would involve additional handling of the animal and thus is not preferred.

5

Other types of viral-derived particles and associated packaging cell lines, such as those based on adenovirus, Epstein-Barr virus, or other viruses can also be used. These non-retroviral derived particles can infect non-dividing cells. If used in combination with the retroviral derived particles described above, the maximum 10 number of cells will receive the desired DNA. In addition, particles to deliver DNA can be manufactured *in vitro* and use of these alone or in combination with the above described particles will enhance the number of mammary epithelial cells which incorporate the desired DNA. An example of particles which are constructed *in vitro* is described or referred to in Morsy and Caskey (1997).

15

The present invention is applicable to all mammals and is especially applicable to all non-human mammals. Goats, sheep and cows are preferred. Cows with their inherent large volume milk production are particularly preferred.

20

The packaging cells will attach and survive for a period of time within the mammary gland. The reason for the presence of the cells is to supply a continuous source of the viral-derived particles to trans-infect the maximum number of mammary epithelial cells. Both the packaging cells and the viral-derived particles are eventually destroyed in the mammary gland; however, considering the fragile nature of the 25 particles *in vitro*, they are likely destroyed within days. The cells, by contrast, may persist much longer. When cells were infused into the udder, and the udder subsequently flushed and assayed for the presence of cells (dead and alive), most of the cells could not be flushed out. Cells were seen in the wash for 3 days after infusion; of those cells that were flushed out, a large majority remain viable, 30 suggesting that most of the cells have become attached to the udder. In prior art methods (for example Archer et al. 1994), the particles are infused into the udder

approximately every two days for two weeks. In the present invention no subsequent infusions are necessary. Thus an advantage of the present invention over the prior art is a reduction in the handling of the animal.

5 In prior arts methods (for example, Archer et al. 1994), large scale tissue culture was required to supply sufficient numbers of particles for multiple infusions. An advantage of the present invention over the prior art is that preparation of a large number of particles is not required.

10 In prior arts methods (for example, Archer et al. 1994), the preparation of a stock solution of viral-particles required ultra-centrifugation and resuspension of the particles. A further advantage of the present invention is that no ultracentrifugation is involved. Centrifugation and other handling techniques can destroy the relatively fragile particles. In the present invention, handling of the particles is minimal, 15 increasing the probability that the particles present will remain intact and useful.

The above cited advantages are in addition to the improvement in yield of the compound in the milk, which has already been described above.

20 This method can be used alone or in combination with other methods of the present invention to increase the incorporation of DNA from the viral-derived particles. The additional methods of the present invention are all designed to ensure that the viral-derived particles are correctly positioned to trans-infect the mammary epithelial cells.

25 In one embodiment, the teat canal and udder is first emptied by milking or under negative pressure. Then the udder is flushed with an osmotically-balanced solution which is infused into the teat canal and udder until the udder is full. This solution is removed by milking or under negative pressure and the desired suspension 30 is infused into the udder. In an alternative procedure, the teat canal is not emptied first but is directly filled with an osmotically-balanced solution which is then removed

by milking or under negative pressure.

5 Flushing of the udder serves two purposes; it removes the thick, secreted fluid that is normally present and it forces open the ductwork to allow better access of the packaging cells and viral-derived particles which will be inserted in the next step of the procedure. An example of a suitable osmotically-balanced solution includes saline solution, but can include any other buffered solutions, and also can include the packaging cell grown medium.

10 External massage applied several times a day to the mammary gland improves the circulation of the viral-derived particles and results in more secretory cells in the mammary gland being exposed to the viral-derived particles and thus more cells will incorporate the DNA carried in these particles.

15 In another embodiment, the packaging cells are grown on a commercially available matrix (designed to support growth and replication of tissue culture cells). This solid support matrix can include gelatin, glass, collagen or plastic beads. Cytodex beads or Cultisphere (purchased from Sigma) are two specific examples of useful support means. The beads, with cells adhering to them, are infused into the 20 mammary gland through the teat canal along with a suspension of DNA-containing viral-derived particles. The beads remain in the mammary gland. External massage applied several times a day to the mammary gland recirculates the beads and helps to distribute the viral-derived particles that are produced by the packaging cells growing on the beads. The presence of the packaging cells on beads also ensures the 25 continuous presence of many more DNA-containing viral-derived particles. Concomitantly more secretory cells in the mammary gland will incorporate the DNA carried within these viral particles and the production of the desired protein will increase accordingly. The beads and any cells remaining on them will eventually be removed when milking is begun.

beads) and viral-derived particles containing the desired DNA is followed by infusion of a substance which is more dense than the water-based suspension fluids, used for cell infusion, such as growth medium (Dulbecco's modified Eagle's medium [DMEM], phosphate buffered saline [PBS], etc.). This dense fluid, which in one example is composed of silicone, displaces the aqueous solutions containing the packaging cells and the viral-derived particles upwards into the ductwork of the mammary gland. This prevents collection of the packaging cells in the cistern of the udder and positions the viral-derived cells and the viral-derived particles up into the ducts of the mammary gland. Thus, the viral-derived particles are positioned near the dividing cells in the alveoli of the mammary gland and allow more of the DNA carried in the viral-derived particles to be incorporated. Any physiologically compatible inert fluid that has a density greater than that of the infusion solution can be used according to this embodiment of the present invention.

15 Thus, the present invention consists of the following procedure, which can be used alone or in combination with optional methods of the present invention, to deliver heterologous DNA to milk producing cells. In this procedure the following steps occur:

- 20 1) A vector containing the desired DNA sequence(s) is constructed and is transfected by standard means into a packaging cell line.
- 25 2) A solution containing the packaging cell line, producing viral-derived particles containing the desired DNA sequence(s), and viral-derived particles, is infused into the mammary gland through the teat canal. The packaging cells attach to the epithelial cells of the mammary gland, remain viable and produce viral-derived particles.
- 30 3) The DNA becomes incorporated into the secretory cells of the mammary gland.
- 4) The milk containing the product induced by addition of the desired DNA is milked from the cistern. The product is purified from the milk or the milk, containing the product, is consumed.

The basic technique can be modified by the addition of one or more of the following steps:

- 1) The udder is flushed with an osmotically-balanced solution.
- 2) The packaging cells are grown on a matrix designed to support proliferation of eukaryotic cells, such as Cytodex beads, and then infused through the teat canal. The cells will remain in the mammary gland and continue to produce viral-derived particles for a period of at least 3 days.
- 3) After infusion of the packaging cells (either as a suspension or grown on a matrix), a compound which is denser than aqueous solutions, such as silicone, is infused into the mammary gland to force the aqueous solutions carrying the packaging cells and viral-derived particles up and into the region of the mammary gland where the DNA can be incorporated into the milk producing cells. The dense compound, if it has been added, and any unattached cells as well as the matrix, if used, is removed from the mammary gland cistern by milking at an appropriate time after infusion. An appropriate time is defined as after the majority of packaging cells attach and after there is sufficient production of viral-derived particles. An example of an appropriate time would be at least 3 days, however shorter or longer periods may also be used. The packaging cells which are not removed at this time die and are removed by the recipient's natural mechanisms.
- 4) External massage applied several times a day to the mammary gland will recirculate the viral-derived particles and the packaging cells, provided either as a suspension or grown on a matrix. This helps to distribute the viral-particles and the cells and increases the incorporation of the DNA carried in these particles into the secretory cells.

25

While this invention is described in detail with particular reference to preferred embodiments thereof, said embodiments are offered to illustrate but do not limit the invention.

EXAMPLES**Example 1: Preparation of plasmids carrying the desired gene and various control sequences for use in retroviral particle delivery to bovine mammary epithelial cells**

5 As a system to transfect the mammary epithelial cells with a desired gene, the PG13 packaging cell line was acquired under license from Fred Hutchinson Cancer Research Center. This system was used because it produces retroviral particles containing the gibbon ape leukemia virus envelope (Galv) which facilitates transfection of bovine cells. To package the desired gene "X" into retroviral particles, 10 the plasmids, pLXSN, pLNCX, pLNSX and pLN, also were acquired under license from Fred Hutchinson Cancer Research Center.

Modifications of plasmids:

15 In order to have an alternative method to select cell clones containing the desired gene, we replaced the *neomycin (neo)* gene with the *hygromycin (hyg)* gene in pLXSN, pLNSX and pLNCX. This was done by long-range PCR-amplification of the region around the *neo* gene then ligating the PCR product with the *hyg* gene which was amplified from the plasmid pREP4 (purchased from Invitrogen). The resulting plasmids were called pLXSH, pLHSX and pLHCX where "L" represents the Moloney 20 murine virus long terminal repeat (LTR) acting as a promoter, "S" is the SV40 promoter and "C" is the cytomegalovirus promoter region.

25 To put the desired gene, "X", under the control of a constitutive promoter, the cytomegalovirus promoter region in pLNCX and pLHCX was removed by restriction digestion and replaced with the beta actin promoter to make pLNAX and pLHAX. The beta actin promoter sequence was derived using PCR from the pJ6Ω plasmid purchased from ATCC (catalog no. 37723).

30 In order to avoid transcription interference between the gene used for selection and the gene used to produce the desired protein, transcription from both genes was coupled by replacing the SV40 promoter from the plasmids pLXSN and pLXSH with

an internal ribosomal entry site (IRES). The resulting plasmids, pLAiN and pLAiH, express both the selection gene and the inserted gene under the same (LTR) promoter. The IRES in these plasmids provides the translation initiation site within the transcript, allowing the downstream gene product to be produced. The IRES used 5 here is identical to the IRES found in the plasmid pIRES1neo purchased from Clontech. The sequences for pLAiN and pLAiH, where A in this case is chicken amylase but which can be any desired protein, are shown in SEQ ID No:1 and SEQ ID No: 2, respectively.

10 In order to increase retroviral titre or stability of the transcript, or to increase the expression level of the desired gene during lactation, or to allow translation of more than one protein from the same transcript, the basic plasmid, pLNCX, was modified. In one modification, the selection gene was removed to minimize the size 15 of the resulting plasmid, pLX. In another modification, the CMV promoter was replaced with the murine mammary tumour virus (M) LTR promoter to improve transcription of the resulting plasmid, pLNMX, during lactation. The sequence for pLNMX is shown in SEQ ID No: 3.

20 In another modification, a wild-type IRES was modified so that the ATG codon at position 10 is destroyed and the sequence downstream of the ATG codon at position 11 codes for the desired gene, "X", in a plasmid such as pLN*M*₂X. The sequence for this IRES modification (i₂) is included within the sequence for pLN*M*₂X, shown in SEQ ID No: 4.

25 **Example 2: Preparation of cell clones producing viral-derived particles carrying the chicken amylase gene as a "marker" protein**

The two packaging cell lines used in this experiment were purchased from ATCC, PA317 (catalog no. CRL-9078) and PG13 (catalog no. CRL-10686). A description of both PA317 and PG13 and their use can be found in Miller et al. 1990.

30

To develop and optimize the transfection of mammary epithelial cells using

the retroviral particle delivery system, we used a stable and readily detectable marker protein, chicken amylase, in some experiments. Chicken amylase migrates at a unique position by native gel electrophoresis and can be differentiated from bovine or other amylases. To produce a PG13-derived cell line (a clone) producing retroviral 5 particles which carried chicken amylase under the control of the beta actin promoter, the following procedure was done.

The pLH(A)amy plasmid with *hygromycin* (H) driven by the LTR promoter and with *amylase* (amy) driven by the beta actin promoter (A), was produced by 10 standard recombinant techniques. pLH(A)amy was transiently transfected by the calcium phosphate technique into the PA317 packaging cell line. The transfected PA317 cells produce viral particles containing the amy RNA into the supernatant. The amphotropic viral envelope protein of these particles allows entry into cells of most species including the PG13 packaging cells in a process called trans-infection. 15 Empirically it has been determined that trans-infection produces PG13 clones with a higher rate of particle production as compared to PG13 clones produced by other means of DNA insertion (particle bombardment, calcium phosphate or liposome transfection). Therefore, the viral-derived particles in the supernatant of the transfected PA317 cells were used to trans-infect the PG13 packaging cell line. The 20 resulting clones were selected using 700 ug/ml hygromycin in DMEM with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin for 14 days. Clones were picked using cloning rings and grown as separate cell lines.

These PG13 amy clones were tested for amylase production by native gel 25 electrophoresis of α -amylase. The α -amylase samples in loading buffer (0.1M tris-borate pH 8.5, 10% sucrose, 10mM magnesium chloride) were electrophoresed for 3-4 hours at 250 volts, with cooling, on a 5.5% acrylamide gel containing 0.1M tris-borate pH 8.5. The electrophoresis buffer was 0.1M tris-borate pH 8.5. The gel was then placed with gentle shaking for 1 h at room temperature in a solution of 2% 30 soluble starch, 10mM calcium chloride, 50mM tris-HCl pH 7.5. The gel was briefly rinsed in water, then placed in a dilute solution of iodine (I_2 : KI : water is about 1 : 2 :

2000) until the amylase signal shows as a clear band on the gel.

All packaging cells produce filled retroviral particles which contain the desired gene and empty particles which do not carry the desired gene. To increase the number 5 of filled retroviral particles, hygromycin-resistant PG13 amy clones producing high amounts of amylase were supertransfected with a second plasmid, pLN(A)amy, which also carried the amylase gene but which has *neomycin* as the clone selection agent. In this procedure, first pLN(A)amy was transfected into the PA317 cell line by the calcium phosphate procedure, and then the viral-derived particles in the 10 supernatant of the transfected PA317 amy-containing cells were used to trans-infect a PG13/pLH(A)amy clone. The PG13/pLH(A) clone which was supertransfected was chosen on the basis of high amylase production. Superclones, containing both pLN(A)amy and pLH(A)amy sequences were obtained by selecting in the presence of 1000 ug/ml G418 and 700 ug/ml hygromycin as described above. The surviving 15 clones were picked and grown up for further testing. Although a marker protein, amylase, was used in these experiments to optimize filling of particles, it is obvious that the same procedure can be done where another protein, such as a pharmaceutical protein, is used instead of the amylase.

20 The superclones producing the highest levels of amylase were analyzed for particle production by the following method. For each clone to be tested, the supernatant containing viral-derived particles was used to trans-infect HeLa 229 (human cervical carcinoma) (purchased from ATCC catalog no. CCL-2.1) and Et2 (bovine mammary) cells (provided by Dr. Boris Zavizion, University of Vermont, 25 Burlington, Vt.). Depending on the resistance gene contained in the plasmid, the trans-infected cells were treated with either 700 ug/ml hygromycin or 1000 ug/ml neomycin, or both, and the resulting colonies were counted. Each colony is the result of one infective (filled) particle. The clone producing the highest number of colonies was selected to be grown for subsequent infusion into the heifer udder. In the specific 30 example shown in Figure 1, clone 10 produced the highest number of viral-derived particles and was designated as PG13/LH/LN(A)amy.

Before a clone can be infused into the udder, it must be tested to determine that it does not produce replication-competent (called "helper") virus. Gene therapy is based on the assumption that the viral-derived particles can carry the desired DNA (i.e. cDNA for amylase or another protein) into the target cell but that once in the cell, 5 the virus cannot reproduce itself. There are two methods to check if helper virus is being produced by the trans-infected packaging cell line. These are described in detail in Cepko, 1992. The first method is to analyze the supernatant of the HeLa and Et2 cells for horizontal spread of hygromycin and/or neomycin resistance. The second method is to look for the presence of reverse transcriptase above background 10 levels in the supernatant of the trans-infected HeLa and Et2 cells. If trans-infection with the supernatant from HeLa and Et2 cells does not produce hygromycin and/or neomycin resistant colonies and if there is no reverse transcriptase above the level found in control cells, then it can be assumed that the particle producing clone, in this 15 case PG13/LH/LN(A)amy, is not producing "helper" virus and therefore can be used for infusion into the udder. We followed the procedures detailed in the Cepko reference and found neither colony nor reverse transcriptase production.

Example 3: Infusion of clones producing retroviral-derived particles which carry a desired gene such as the amylase marker protein

20 In one example, the cell clone PG13/LH/LN(A)amy, which expresses chicken amylase as a marker protein, was infused into the udder of a 7 month pregnant heifer, #99. Before infusion with the cell clone, each quarter of the udder was flushed with 250ml of saline solution at 37° C using the catheter portion of an angiocath G-18 catheter attached to a 140 cc Monoject syringe with a Luer lock attachment (both 25 purchased from CDMV, Saint-Hyacinthe, Quebec). The infusate was then milked out and measured to determine the volume of cell solution which could be administered to this particular quarter of this specific heifer.

30 Two superclones, designated as PG13/LH/LN(A)amy Clone 10 and PG13/LH/LN(A)amy Clone 12, were grown in standard tissue culture flasks until the total cell number (in an appropriate number of flasks) was $>2 \times 10^8$ cells/clone. The

cells were trypsinized, counted and resuspended at 1×10^8 cells in 250 ml DMEM without serum but containing 80 ug/ml of Polybrene to facilitate particle adsorption to the mammary epithelial cells.

5 The udder has four separate quarters. The left front quarter was left untouched as a negative control (LF-). The front right quarter was flushed with saline and infused with 250 ml DMEM plus 80 ug/ml Polybrene but with NO cells added and served as a negative control (RF-). The right hind quarter was infused with 1×10^8 Clone 12 cells in 250 ml DMEM plus Polybrene (RH+) and the left hind quarter was infused 1×10^8 Clone 10 cells in 250 ml DMEM plus Polybrene (LH+). The infusate was not removed. The udder was massaged 3 times a day, morning, noon and night, to help to distribute the cells which tend to settle into the cistern of the udder. Three weeks post infusion, the udder was "stripped" (all secretions were milked by hand from each quarter) which removed about 7 to 10 ml per quarter of a viscous, serum-like fluid. This was designated as "early premilk". Eight weeks post infusion the udder was stripped again, producing about 25 ml per quarter of a slightly cloudy, viscous fluid designated as "late premilk". The samples from the right front control quarter RF(-) and the two infused quarters, the right hind, RH(+) and the left hind, LH(+) were analyzed for the presence of active amylase as previously described (see 10 Figure 1).

15 Figure 1 shows that in the early premilk sample, amylase is present in both infused quarters (RH) and (LH) while the control quarter (RF) contains no amylase. In the late premilk, the negative control quarter (RF) continues to show no amylase 20 activity. Clone 10, left hind quarter, shows the highest amylase activity. Clone 12, right hind quarter, has decreased activity compared to the early premilk sample, but a small amount of amylase activity was detected. The samples loaded represent equal 25 volumes (100 ul/lane) of the premilk samples. No attempt was made to load equal amounts of protein. The apparent reduction in the amount of amylase present between 30 early and late premilk samples is caused by increased volume of the late premilk samples relative to the volume of the early premilk samples.

Figure 1 shows that in the early premilk sample, amylase is present in both

infused quarters (RH) and (LH) while the control quarter (RF) contains no amylase.

In the late premilk, the negative control quarter (RF) continues to show no amylase

activity. Clone 10, left hind quarter, shows the highest amylase activity. Clone 12,

right hind quarter, has decreased activity compared to the early premilk sample, but a

small amount of amylase activity was detected. The samples loaded represent equal

volumes (100 ul/lane) of the premilk samples. No attempt was made to load equal

amounts of protein. The apparent reduction in the amount of amylase present between

early and late premilk samples is caused by increased volume of the late premilk

samples relative to the volume of the early premilk samples.

Example 4: Preparation of a clone producing viral-derived particles that carry the tPA gene and infusion of this clone into the udder of a pregnant heifer

Tissue plasminogen activator (tPA) is used to treat heart attack and stroke by dissolving blood clots. We selected human tPA to be the first pharmaceutical product to be produced by our method in bovine milk. The ptPA-K plasmid, containing the mutated cDNA sequence for human tPA (where the amino acids KHRR 296-299 was mutated to AAAA, i.e. the "K" mutation), was purchased from ATCC (American Type Culture Collection, catalog no. 68059). Two additional mutations were incorporated into ptPA-K to form ptPA-TNK: the amino acid threonine at position 103 was mutated to asparagine (the "T" mutation), and the amino acid asparagine at position 117 was mutated to glutamine (the "N" mutation). The tPA amino acid sequence and a description of the above modifications can be found in Pennica et al.1983. Both mutations were produced by using mismatched oligonucleotides containing the altered nucleotide sequence as primers for PCR amplification. The tPA-TNK gene was subsequently excised by restriction digestion and ligated into the pLXSH plasmid to make pL(tPA)SH.

The resulting PG13(tPA) clones were analyzed for tPA production by colorimetric determination using Spectrozyme (# 444 purchased from American Diagnostica Inc.). Clones which showed high levels of tPA were then checked for production of filled particles by colony counts (as described previously) and were safety checked to insure that no replication competent virus was being produced and that there was no reverse transcriptase production above that found as background in HeLa or ET2 cells. None of the clones tested produced replication competent virus by either of these tests. The clones with the highest particle production and highest level of tPA production were selected to be grown for infusion into the udder. In the following example, clone PG13/L(tPA)SH-1, was chosen for infusion into the udder.

In one example, Clone 1 (PG13/L(tPA)SH-1), which produces tPA, was infused into the udder of a seven and a half month pregnant heifer, #90 and into the

udder of a six and a half month pregnant heifer, #56. Before infusion of the clone and particles produced by it, each quarter of the udder in both heifers was flushed with 250ml of saline as described in Example 3. After milking out the saline, the right rear (RR) quarter of heifer #90 received 2.5×10^7 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum while the right front (RF) quarter received 1×10^8 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum. The left front (LF) quarter received 250 ml of DMEM as a control while the left rear (LR) quarter was the untreated control. Heifer # 56 received 2.5×10^7 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the left front quarter (LF+) and 1×10^8 cells of Clone 1 plus 80 ug/ml Polybrene in 250 ml of DMEM without serum in the right rear quarter (RR+). The right front quarter received 250 ml of DMEM as a control (RF-) while the left front (LF-) quarter was the untreated control. In both heifers, the infusate was not removed and the udder was massaged three times daily to help distribute the cells and particles up into the ductwork.

15

Four weeks post-infusion, the four quarters of both heifers were stripped to remove 5 to 9ml of the viscous, serum-like premilk fluid. The premilk samples from treated and control quarters of both heifers were analyzed for the presence of tPA by Western blotting. A Western blot showing the tPA results obtained from the best quarter of each heifer is shown in Figure 2.

For Western blotting, the premilk samples were adjusted to pH 4.5 with acetic acid and centrifuged at 13,000 x g to pellet the "curd" fraction. The "whey" fraction contained in the supernatant was collected and diluted 1:5 with sample buffer. Samples of 20 ul were loaded onto a 7.5% SDS PAGE gel. To detect tPA, the gel was transferred to nitrocellulose and then blocked overnight in 5% bovine serum albumin (BSA). The blot was incubated for 2 hours with a polyclonal antibody to tPA, #385R, purchased from American Diagnostica, diluted 1:500 with PBS followed by extensive washing in PBS. The secondary antibody, horseradish peroxidase goat-anti-rabbit, diluted 1:5000 in PBS, was incubated with the blot for one hour then extensively washed. Detection of antibody staining of tPA was by enhanced chemi-

luminescence (ECL) Amersham Detect Kit. Specificity of the primary antibody was previously determined by Western blotting a control sample of commercial tPA purchased from American Diagnostica.

5 Results of Western blotting samples obtained from the untreated control quarter (LF-) and from one treated quarters of each heifer are shown in Figure 2. Lane 1 shows a strong tPA band in the premilk from the treated (LH+) quarter of heifer #56. The middle lane, lane 2, contains premilk from the (LF-) control quarter of cow #56. Lane 3 shows a tPA band in the premilk from the treated (RF+) quarter 10 of heifer #90. A faint smear in all 3 sample lanes is the result of non-specific binding of the antibody to an unidentified protein and should be disregarded.

15 **Example 5: Determination of viability and attachment of 3T3 cells to the surface of the bovine udder.**

16 The cells used in this experiment were 3T3 cells (purchased from ATCC, catalog no. CCL-92) which had been transfected with luciferase as a marker protein. These 3T3 cells are essentially identical to the PG13 packaging cells except that the 3T3 cells have not been transfected with the retroviral genes that are found in the 20 packaging line.

17 Three quarters of the udder of a 5 month pregnant heifer and three quarters of the udder of a 7 month pregnant heifer were flushed with saline solution at 37° C using a standard veterinary infusion apparatus. The saline was then milked out and 25 measured to determine what quantity of medium with or without cells could be infused into that particular quarter. In both heifers, one udder quarter was left untreated as a negative control; a second quarter received only DMEM, the third quarter received 1 X 10⁶ cells suspended in an appropriate amount of DMEM, and the fourth quarter received 1 X 10⁷ cells also suspended in an appropriate amount of 30 DMEM. The quarters were then milked to produce about 10 ml of fluid at 3 hours, 24 hours, and 72 hours post-infusion.

The fluid obtained by milking was divided in half. One portion was cultured under standard conditions for 3T3 cells to determine if the cells were viable. The second portion was used in a luciferase assay to count the approximate number of 3T3-luciferase cells per ml in the fluid. A control was run simultaneously using 5 known numbers of 3T3-luciferase cells and a curve drawn to determine the correlation of luciferase intensity with cell number.

The results of two experiments indicated that the highest number of cells were found 3 hours post infusion and progressively fewer cells were found in the fluid 10 milked from the udder at 24 and 72 hours. However the cells which were milked out at 72 hours were viable. This is evidence that the cells are attaching to the udder surface and that those cells which were unattached (and therefore could be milked out of the udder) remained viable for the period of the experiment. This suggests that the 3T3 cells are not quickly destroyed by the factors in the environment of the udder. 15 Thus PG13(tPA) cells can be expected to remain viable for at least a period of 3 days during which time they will continue to produce viral-derived particles and can therefore trans-infect a substantial number of mammary epithelial cells.

Table 1: Attachment of 3T3 cells to udder walls

Udder Quarter	Treatment	Attachment of 3T3 cells to udder interior at:		
		3 hours post-infusion	24 hours post-infusion	72 hours post-infusion
left hind	no treatment	-	-	-
left front	medium only	-	-	-
right hind	1×10^6 cells	-	+/-	+
right front	1×10^7 cells	+/-	++	++

Example 6: Infusion of 3T3 cells grown on a solid support means

The cells used in this experiment were 3T3 cells, as described in Example 2.

In this example however the cells were grown on Cytodex beads.

The cells growing on beads were infused into the udder of a 7 month pregnant heifer and subsequently removed 1, 2 and 3 days later as described in Example 2. Cells
5 were removed from beads and viability was determined by Trypan blue exclusion. The cells remained viable for the entire period.

Example 7: Use of Silicone to displace the cells and viral-derived particles

The cells used in this experiment were 3T3 cells, as described in Example 3.
10 The volume of the solution containing the cells and viral-derived particles was reduced by 50 ml, 25 ml, or 10 ml but the overall number of the cells remained constant.

15 After the solution was infused into the udder, as described in the preceding examples, approximately 50 ml, 25 ml or 10 ml of silicone was infused into the mammary gland, using the methods previously described.

20 After three days the silicone was removed from the cistern by milking. No reaction to the silicone was noted.

All scientific publications and patent documents are incorporated herein by reference.

References:

25 Archer, J.S., W.S. Kennan, M.N. Gould, R.D. Bremel. 1994. Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors. Proc. Natl. Acad. Sci. USA, 91:6840-6844.

30 Cepko, C. 1992. Transduction of genes using retrovirus vectors. *In: Short Protocols*

in Molecular Biology, 2nd edition. Ed. F.M. Ausubel, R. Brent, R.E. Kingston, D.D. Moore, J.G. Seidman, J.A. Struhl. Pub. by John Wiley & Sons. New York, N.Y. pp 9-30 to 9-45.

5 Furth, P.A., A. Shamay, R.J. Wall, L. Henninghausen. 1992. Gene transfer into somatic tissues by jet injection. *Analyst Biochem.* 205:365-368.

Miller, A.D., D.G. Miller, J. V. Garcia, C.M. Lynch. 1990. Use of retroviral vectors for gene transfer and expression. *Meth. Enzymol.* 217: 581-599.

10 Morsy, M.A. and C.T. Caskey. 1997. Safe gene vectors made simpler. *Nature Biotech.* 15:17.

Pennica, D, W.E. Holmes, W.J. Kohr, R.N. Harkins, G.A. Vehaar, C.A. Ward, W.F. Bennett, E. Yelverton, P.H. Seburg, H.L. Heyneker, D.V. Goeddel. 1983. Cloning and expression of human tissue-type plaminogen activator cDNA in *E. coli*. *Nature* 301: 214-221.

15 Thierry, A.R., Y. Lunardi-Iskandar, J.L. Bryant, P. Rabinovich, R.C. Gallo, L.C. Mahan. 1995. Systemic gene therapy: Biodistribution and long-term expression of a transgene in mice. *Proc. Natl. Acad. Sci. USA.* 92:9742-9746.

20 The present invention has been described with regard to preferred embodiments. However, it will be obvious to persons skilled in the art that a number of variations and modifications can be made without departing from the scope of the invention as described in the following claims.

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: Her Majesty in Right of Canada as Rep. by Agriculture and Agri-Food Canada
- (B) STREET: Experimental Farm
- (C) CITY: Ottawa
- (D) STATE: Ontario
- (E) COUNTRY: Canada
- (F) POSTAL CODE (ZIP): K1A 0C6

(ii) TITLE OF INVENTION: Production of Value-added Milk by Incorporation of Specific DNA Sequences into Mammary Epithelial Cells

(iii) NUMBER OF SEQUENCES: 4

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(v) CURRENT APPLICATION DATA:

APPLICATION NUMBER: CA 0,000,000

(vi) PRIOR APPLICATION DATA:

- (A) APPLICATION NUMBER: CA 2,199,212
- (B) FILING DATE: 05-MAR-1997

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 7699 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GAATTGCTAG CAATTGCTAG CAATTGCTAG CAATTCATAC CAGATCACCG AAAACTGTCC

60

TCCAAATGTG TCCCCCTCAC ACTCCCAAAT TCGCGGGCTT CTGCCTCTTA GACCACTCTA

120

CCCTATTCCC	CACACTCACC	GGAGCCAAAG	CCGCAGCCCT	TCCGTTTCTT	TGCTTTTGAA	180
AGACCCACC	CGTAGGTGGC	AAGCTAGCTT	AAGTAACGCC	ACTTTGCAAG	GCATGGAAAA	240
ATACATAACT	GAGAATAGAA	AAGTCAGAT	CAAGGTCAGG	AACAAAGAAA	CAGCTGAATA	300
CCAAACAGGA	TATCTGTGGT	AAGCGGTTCC	TGCCCCGGCT	CAGGGCCAAG	AACAGATGAG	360
ACAGCTGAGT	GATGGGCCAA	ACAGGATATC	TGTGGTAAGC	AGTTCTGCC	CCGGCTCGGG	420
GCCAAGAACAA	GATGGTCCCC	AGATGCGGTC	CAGCCCTCAG	CAGTTCTAG	TGAATCATCA	480
GATGTTTCCA	GGGTGCCCA	AGGACCTGAA	AATGACCTG	TACCTTATTT	GAACTAACCA	540
ATCAGTTCGC	TTCTCGCTTC	TGTCGCGCG	CTTCCGCTCT	CCGAGCTCAA	AAAAAGAGCC	600
CACAACCCCT	CACTCGGCAG	GCCAGTCTTC	CGATAGACTG	CGTCGCCCGG	GTACCCGTAT	660
TCCAATAAA	GCCTCTTGCT	GTTTGCATCC	GAATCGTGGT	CTCGCTGTT	CTTGGGAGGG	720
TCTCCTCTGA	GTGATTGACT	ACCCACGACG	GGGGTCTTTC	ATTTGGGGGC	TCGTCCGGGA	780
TTTGGAGACC	CCTGCCAGG	GACCACCGAC	CCACCACCGG	GAGGTAAGCT	GGCCAGCAAC	840
TTATCTGTGT	CTGTCGGATT	GTCTAGTGTC	TATGTTGAT	GTTATGCGCC	TGGCTCTGTA	900
CTAGTTAGCT	AACTAGCTCT	GTATCTGGCG	GACCCGTGGT	GGAACTGACG	AGTTCTGAAC	960
ACCCGGCCGC	AACCCTGGGA	GACGTCCAG	GGACTTTGGG	GGCCGTTTTT	GTGGCCCGAC	1020
CTGAGGAAGG	GAGTCGATGT	GGAATCCGAC	CCCGTCAGGA	TATGTGGTTC	TGGTAGGAGA	1080
CGAGAACCTA	AAACAGTTCC	CGCCTCCGTC	TGAATTTTG	CTTTCGGTTT	GGAACCGAAG	1140
CCGCGCGTCT	TGTCTGCTGC	AGCGCTGCAG	CATCGTTCTG	TGTTGTCTCT	GTCTGACTGT	1200
GTTTCTGTAT	TTGTCTGAAA	ATTAGGGCCA	GACTGTTACC	ACTCCCTTAA	GTTTGACCTT	1260
AGGTCACTGG	AAAGATGTCG	AGCGGATCGC	TCACAACCAG	TCGGTAGATG	TCAAGAAGAG	1320
ACGTTGGGTT	ACCTCTGCT	CTGCAGAATG	GCCAACCTTT	AACGTGGAT	GGCCCGCGAGA	1380
CGGCACCTTT	AACCGAGACC	TCATCACCCA	GGTTAAGATC	AAGGTCTTTT	CACCTGGCCC	1440
GCATGGACAC	CCAGACCAGG	TCCCCTACAT	CGTGACCTGG	GAAGCCTTGG	CTTTGACCC	1500
CCCTCCCTGG	GTCAAGCCCT	TTGTACACCC	TAAGCCTCCG	CCTCCTCTTC	CTCCATCCGC	1560
CCCGTCTCTC	CCCCCTGAAC	CTCCTCGTTC	GACCCCGCCT	CGATCCTCCC	TTTATCCAGC	1620
CCTCACTCCT	TCTCTAGGCG	CCGGAATTGCG	TTAACTCGAC	ATGGAAGTCC	TTCTCCTCCT	1680
CGCAGCTGTC	GGGCTTGCT	GGGCACAGTA	CAATCCAAAC	ACTCAGGCTG	GGAGGACATC	1740
TATCGTGCAT	CTCTTGAAT	GGCGCTGGGC	CGACATTGCA	CTGGAGTGC	AAACACTATTT	1800

AGCTCCTAAT GGGTTGGAG GAGTCAGGT TTCTCCTCCA AATGAAAACA TTGTCATTAC	1860
TAATCCGAAC AGGCCCTGGT GGGAAAGATA CCAGCCCATC AGCTACAAGA TCTGCAGTCG	1920
ATCGGGCAAT GAAAATGAAT TCAGAGACAT GGTGACCAGA TGCAACAATG TTGGAGTTCG	1980
TATTTATGTG GATGCTGTTG TCAATCACAT GTGTGGATCT ATGGGTGGCA CGGGCACCCA	2040
CTCAACATGT GGGAGCTATT TCAACACCGG GACTAGAGAT TTTCCCGCTG TGCGTACTC	2100
TGCCTGGAT TTCAATGACG GCAAATGTCA CACTGCAAGT GGAGACATCG AAAATTATGG	2160
GGACATGTAT CAGGTCCGGG ATTGCAAGTT GTCCAGCCTT CTTGATCTGG CTCTGGAGAA	2220
GGACTATGTA CGCTCAACAA TTGCAGCGTA CATGAATCAC CTCATTGATA TGGGTGTAGC	2280
AGGGTTCCGG ATCGATGCTG CCAAGCATAT GTGGCCAGGG GACATAAGAG CGTTTCTGGA	2340
CAAAC TGCAAC GATCTAAATA CTCAGTGGTT TTCAGCAGGA ACGAAACCCCT TTATTTACCA	2400
AGAGGTAATT GACTTGGAG GAGAGCCAAT CACAGGCAGT CAGTACTTTG GGAATGGCCG	2460
CGTGACAGAA TTCAAGTATG GTGCCAAACT GGGGACGGTG ATCCGGAAGT GGAATGGAGA	2520
GAAGATGGCC TACTTAAAGA ACTGGGGAGA AGGCTGGGC TTTGTGCCCTT CTGACAGAGC	2580
CCTGGTGTTC GTGGATAACC ACGACAACCA GCGGGGGCAC GGGGCAGGCG GAGCTTCCAT	2640
TCTTACTTTTC TGGGATGCCA GGCTTTATAA AATGGCGTT GGTTTCATGC TCGCTCATCC	2700
GTACGGGTTTC ACACGGGTGA TGTCAAGTTA TCGTTGGCCA AGATATTCG AAAACGGAGT	2760
GGATGTTAAC GACTGGGTGG GACCACCAAG TAACTCGGAC GGATCGACGA AGTCCGTTAC	2820
AATCAACGCA GACACTACCT GTGGCAATGA CTGGGTCTGC GAACATCGCT GGCGACAAAT	2880
AAGGAACATG GTTATCTTCC GTAAATGTGGT AGACGGTCAG CCTTTCTCAA ACTGGTGGGA	2940
CAACGGGAGC AATCAAGTAG CTTTCGGTCG CGGCGACAGA GGCTTCATTG TCTTTAATAA	3000
TGATGACTGG TATATGAATG TCGATTTGCA AACTGGTCTG CCTGCTGGAA CCTACTGCGA	3060
TGTTATTTCT GGACAAAAGG AAGGCAGTGC GTGTACTGGA AAGCAGGTGT ACGTTTCCCTC	3120
GGATGGAAAG GCCAATTTCAG AGATTAGTAA CAGCGATGAA GATCCATTG TTGCAATTCA	3180
CGTTGATGCC AAGTTATAAG CTTCGAGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA	3240
TTCGGCTTGT CGACATCTAG GGCGGCCAAT TCCGGCCCTC TCCCCCCCCC CCCTAACGTT	3300
ACTGGCCGAA GCCGCTTGGA ATAAGGCCGG TGTGTGTTTG TCTATATGTG ATTTTCCACC	3360
ATATTGCCGT CTTTTGGCAA TGTGAGGGCC CGGAAACCTG GCCCTGTCTT CTTGACGAGC	3420
ATTCCCTAGGG GTCTTTCCCC TCTCGCCAAA GGAATGCAAG GTCTGTGAA TGTGCGTGAAG	3480

GAAGCAGTTC CTCTGGAAGC TTCTTGAAGA CAAACACCGT CTGTAGCGAC CCTTTGCAGG	3540
CAGCGGAACC CCCCACCTGG CGACAGGTGC CTCTGCGGCC AAAAGCCACG TGTATAAGAT	3600
ACACCTGCAA AGGCGGCACA ACCCCAGTGC CACGTTGTGA GTTGGATAGT TGTGGAAAGA	3660
GTCAAATGGC TCTCCTCAAG CGTAGTCAAC AAGGGGCTGA AGGATGCCA GAAGGTACCC	3720
CATTGTATGG GAATCTGATC TGGGGCCTCG GTGCACATGC TTTACATGTG TTTAGTCGAG	3780
GTAAAAAAAG CTCTAGGCCC CCCGAACCAC GGGGACGTGG TTTTCCTTTG AAAAACACGA	3840
TGATAAGCTT GCCACAACCC GGGATAATTG CTGCAGCAA TATGGGATCG GCCATTGAAC	3900
AAGATGGATT GCACGCAGGT TCTCCGGCCG CTTGGGTGGA GAGGCTATTG GGCTATGACT	3960
GGGCACAACA GACAATCGGC TGCTCTGATG CCGCCGTGTT CCGGCTGTCA GCGCAGGGGC	4020
GCCCCGTTCT TTTTGTCAAG ACCGACCTGT CCGGTGCCCT GAATGAACTG CAGGACGAGG	4080
CAGCGCGGCT ATCGTGGCTG GCCACGACGG GCGTTCTTG CGCAGCTGTG CTGACGTTG	4140
TCACTGAAGC GGGAAAGGGAC TGGCTGCTAT TGGGCGAAGT GCCGGGGCAG GATCTCCTGT	4200
CATCTCACCT TGCTCCTGCC GAGAAAGTAT CCATCATGGC TGATGCAATG CGGCGGCTGC	4260
ATACGTTGA TCCGGCTACC TGCCCATTG ACCACCAAGC GAAACATCGC ATCGAGCGAG	4320
CACGTACTCG GATGGAAGCC GGTCTTGTG ATCAGGATGA TCTGGACGAA GAGCATCAGG	4380
GGCTCGCGCC AGCCGAACTG TTCCGCAGGC TCAAGGCGCG CATGCCGAC GGCGATGATC	4440
TCGTCGTGAC CCATGGCGAT GCCTGCTTGC CGAATATCAT GGTGGAAAAT GGCGCTTTT	4500
CTGGATTCAT CGACTGTGGC CGGCTGGGTG TGGCGGACCG CTATCAGGAC ATAGCGTTGG	4560
CTACCCGTGA TATTGCTGAA GAGCTTGGCG GCGAATGGGC TGACCGCTTC CTCGTCTTT	4620
ACGGTATCGC CGCTCCCGAT TCGCAGCGCA TCGCCTTCTA TCGCCTTCTT GACGAGTTCT	4680
TCTGAGCGGG ACTCTGGGT TCGATAAAAT AAAAGATTTT ATTTAGTCTC CAGAAAAAGG	4740
GGGGAATGAA AGACCCACC TGTAGGTTG GCAAGCTAGC TTAAGTAACG CCATTTGCA	4800
AGGCATGGAA AAATACATAA CTGAGAATAG AGAAGTTCAAG ATCAAGGTCA GGAACAGATG	4860
GAACAGCTGA ATATGGCCA AACAGGATAT CTGTGGTAAG CAGTTCTGC CCCGGCTCAG	4920
GGCCAAGAAC AGATGGAACA GCTGAATATG GGCAAACAG GATATCTGTG GTAAGCAGTT	4980
CCTGCCCGG CTCAGGCCA AGAACAGATG GTCCCCAGAT GCGGTCCAGC CCTCAGCAGT	5040
TTCTAGAGAA CCATCAGATG TTTCCAGGGT GCCCCAAGGA CCTGAATGA CCCTGTGCCT	5100
TATTTGAACT AACCAATCAG TTGCGCTTCTC GCTTCTGTTC GCGCGCTTCT GCTCCCCGAG	5160

CTCAATAAAA GAGCCCACAA CCCCTCACTC GGGGCGCCAG TCCTCCGATT GACTGAGTCG	5220
CCCGGGTACC CGTGTATCCA ATAAACCCCTC TTGCAGTTGC ATCCGACTTG TGGTCTCGCT	5280
GTTCCCTTGGG AGGGTCTCCT CTGAGTGATT GACTACCCGT CAGCGGGGGT CTTTCATTIG	5340
GGGGCTCGTC CGGGATCGGG AGACCCCTGC CCAGGGACCA CCGACCCACC ACCGGGAGGT	5400
AAGCTGGCTG CCTCGCGCGT TTGGTGATG ACGGTGAAAA CCTCTGACAC ATGCAGCTCC	5460
CGGAGACGGT CACAGCTTGT CTGTAAGCGG ATGCCGGGAG CAGACAAGCC CGTCAGGGCG	5520
CGTCAGCGGG TGGTGGCGGG TGTCGGGGCG CAGCCATGAC CCAGTCACGT AGCGATAGCG	5580
GAGTGTATAAC TGGCTTAACAT ATGCCGCATC AGAGCAGATT GTACTGAGAG TGCACCATAT	5640
GCGGTGTGAA ATACCGCACA GATGCGTAAG GAGAAAATAC CGCATCAGGC GCTCTTCCGC	5700
TTCCTCGCTC ACTGACTCGC TGCCTCGGT CGTTGGCTG CGGCAGCGG TATCAGCTCA	5760
CTCAAAGGCG GTAATACGGT TATCCACAGA ATCAGGGGAT AACGCAGGAA AGAACATGTG	5820
AGCAAAAGGC CAGCAAAAGG CCAGGAACCG TAAAAAGGCC GCGTTGCTGG CGTTTTCCA	5880
TAGGCTCCGC CCCCCTGACG AGCATCACAA AAATCGACGC TCAAGTCAGA GGTGGCGAAA	5940
CCCGACAGGA CTATAAAGAT ACCAGGCCTT TCCCCCTGGA AGCTCCCTCG TGCGCTCTCC	6000
TGTTCCGACC CTGCCGCTTA CGGGATACCT GTCCGCCMTT CTCCCTCGG GAAGCGTGGC	6060
GCTTTCTCAT AGTCACGCT GTAGGTATCT CAGTTGGTG TAGGTCGTTG GCTCCAAGCT	6120
GGGCTGTGTG CACGAACCCC CCGTTCAAGCC CGACCGCTGC GCCTTATCCG GTAATATCG	6180
TCTTGAGTCC AACCCGGTAA GACACGACTT ATGCCACTG GCAGCAGCCA CTGGTAACAG	6240
GATTAGCAGA GCGAGGTATG TAGGCGGTGC TACAGAGTTC TTGAAGTGGT GGCTTAACTA	6300
CGGCTACACT AGAAGGACAG TATTTGGTAT CTGCGCTCTG CTGAAGCCAG TTACCTTCGG	6360
AAAAAGAGTT GGTAGCTCTT GATCCGGCAA ACAAAACCACC GCTGGTAGCG GTGGTTTTTT	6420
TGTTTGCAAG CAGCAGATTA CGCGCAGAAA AAAAGGATCT CAAGAAGATC CTTTGATCTT	6480
TTCTACGGGG TCTGACGCTC AGTGGAACGA AAAACTCACGT TAAGGGATTT TGGTCATGAG	6540
ATTATCAAAA AGGATCTCA CCTAGATCCT TTTAAATTAA AAATGAAGTT TTAAATCAAT	6600
CTAAAGTATA TATGAGTAAA CTTGGTCTGA CAGTTACCAA TGCTTAATCA GTGAGGCACC	6660
TATCTCAGCG ATCTGTCTAT TTGCTTCATC CATAGTTGCC TGACTCCCCG TCGTGTAGAT	6720
AACTACGATA CGGGAGGGCT TACCATCTGG CCCCAGTGCT GCAATGATAC CGCGAGACCC	6780
ACGCTCACCG GCTCCAGATT TATCAGCAAT AAACCAGCCA GCCGGAAGGG CCGAGCGCAG	6840

AAGTGGTCCT GCAACTTAT CCGCCTCCAT CCAGTCTATT AATTGTTGCC GGGAAAGCTAG	6900
AGTAAGTAGT TCGCCAGTTA ATAGTTGCG CAACGTTGTT GCCATTGCTG CAGGCATCGT	6960
GGTGTACCGC TCGTCGTTG GTATGGCTTC ATTCAAGCTCC GGTTCCCAAC GATCAAGGCG	7020
AGTTACATGA TCCCCATGT TGTGCAAAAA AGCGGTTAGC TCCTTCGGTC CTCCGATCGT	7080
TGTCAGAAGT AAGTTGGCCG CAGTGTATC ACTCATGGTT ATGGCAGCAC TGCTATAATT	7140
TCTTACTGTC ATGCCATCCG TAAGATGCTT TTCTGTGACT GGTGAGTAATC CAACCAAGTC	7200
ATTCTGAGAA TAGTGTATGC GGCAGCCGAG TTGCTCTTGC CCGGCGTCAA CACGGGATAA	7260
TACCGCGCCA CATAGCAGAA CTTTAAAAGT GCTCATCATT GGAAACGTT CTTCGGGGCG	7320
AAAACCTCTCA AGGATCTTAC CGCTGTTGAG ATCCAGTTCG ATGTAACCCA CTCGTGCACC	7380
CAACTGATCT TCAGCATCTT TTACTTCAC CAGCGTTCT GGTTGAGCAA AAACAGGAAG	7440
GCAAAATGCC GCAAAAAAGG GAATAAGGGC GACACGGAAA TGTTGAATAC TCATACTCTT	7500
CCTTTTTCAA TATTATTGAA GCATTTATCA GGGTTATTGT CTCATGAGCG GATAACATATT	7560
TGAATGTATT TAGAAAAATA AACAAATAGG GGTTCCGCGC ACATTTCCCC GAAAAGTGCC	7620
ACCTGACGTC TAAGAAACCA TTATTATCAT GACATTAACC TATAAAAATA GGCGTATCAC	7680
GAGGCCCTTT CGTCTTCAA	7699

(2) INFORMATION FOR SEQ ID NO: 2:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7980 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

GAATTGCTAG CAATTGCTAG CAATTGCTAG CAATTCTACAC CAGATCACCG AAAACTGTCC	60
TCCAAATGTG TCCCCCTCAC ACTCCCAAAT TCGCGGGCTT CTGCCTCTTA GACCACTCTA	120
CCCTATTCCC CACACTCACC GGAGCCAAAG CCGCGGCCCT TCCGTTCTT TGCTTTGAA	180
AGACCCCACC CGTAGGTGGC AAGCTAGCTT AAGTAACGCC ACTTTGCAAG GCATGGAAA	240
ATACATAACT GAGAATAGAA AAGTCAGAT CAAGGTCAAG AACAAAGAAA CAGCTGAATA	300
CCAAACAGGA TATCTGTGGT AAGCGGTTCC TGCCCCGGCT CAGGGCCAAG AACAGATGAG	360

ACAGCTGAGT GATGGGCCAA ACAGGATATC TGTGGTAAGC AGTTCCCTGCC	CCGGCTCGGG	420
GCCAAGAACAA GATGGTCCCC AGATGCGGTC CAGCCCTCAG CAGTTTCTAG	TGAATCATCA	480
GATGTTTCCA GGGTGCCCA AGGACCTGAA AATGACCCCTG TACCTTATTT	GAACTAACCA	540
ATCAGTTCGC TTCTCGCTTC TGTCGCGCG CTTCCGCTCT	CCGAGCTCAA TAAAAGAGCC	600
CACAACCCCT CACTCGGCGC GCCAGTCTTC CGATAGACTG CGTCGCCCGG	GTACCCGTAT	660
TCCCAATAAA GCCTCTTGCT GTTTGCATCC GAATCGTGGT CTCGCTGTT	CTTGGGAGGG	720
TCTCCTCTGA GTGATTGACT ACCCACGACG GGGGTCTTTC ATTTGGGGGC	TCGTCCGGGA	780
TTTGGAGACC CCTGCCAGG GACCACCGAC CCACCACCGG GAGGTAAGCT	GGCCAGCAAC	840
TTATCTGTGT CTGTCCGATT GTCTAGTGTC TATGTTGAT GTTATGCC	TGGCTCTGTA	900
CTAGTTAGCT AACTAGCTCT GTATCTGGCG GACCCGTGGT GGAAC TGACG	AGTTCTGAAC	960
ACCCGGCCGC AACCCCTGGGA GACGTCCCAG GGACTTTGGG GGCCGTTTT	GTGGCCCGAC	1020
CTGAGGAAGG GAGTCGATGT GGAATCCGAC CCCGTCAGGA TATGTGGTTC	TGGTAGGAGA	1080
CGAGAACCTA AAACAGTTCC CGCCTCCGTC TGAATTGTTG CTTTCGGTTT	GGAACCGAAG	1140
CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG CATCGTTCTG TGGTGTCTCT	GTCTGACTGT	1200
GTTTCTGTAT TTGTCTGAAA ATTAGGGCCA GACTGTTACC ACTCCCTTAA	GTTTGACCTT	1260
AGGTCACTGG AAAGATGTCG AGCGGATCGC TCACAACCAAG TCGGTAGATG	TCAAGAAGAG	1320
ACGTTGGTTT ACCTTCTGCT CTGCAGAATG GCCAACCTTT AACGTCGGAT	GGCCCGCGAGA	1380
CGGCACCTTT AACCGAGACC TCATCACCCA GGTAAAGATC AAGGTCTTTT	CACCTGGCCC	1440
GCATGGACAC CCAGACCAGG TCCCCTACAT CGTGACCTGG GAAGCCTTGG	CTTTGACCC	1500
CCCTCCCTGG GTCAAGCCCT TTGTACACCC TAAGCCTCCG CCTCCTCTTC	CTCCATCCGC	1560
CCCGTCTCTC CCCCTTGAAC CTCCCTGTTG GACCCCGCT CGATCCCTCC	TTTATCCAGC	1620
CCTCACTCCT TCTCTAGGCG CCGGAATTG TTAACTCGAC ATGGAAGTCC	TTCTCCTCCT	1680
CTCAGCTGTC GGGCTTGCT GGGCACAGTA CAATCCAAAC ACTCAGGCTG	GGAGGACATC	1740
TATCGTGCAT CTCTTGAAT GGCCTGGGC CGACATTGCA CTGGAGTGC	AAACACTATTT	1800
AGCTCCTAAT GGGTTGGAG GAGTCAGGT TTCTCCTCCA AATGAAAACA	TTGTCATTAC	1860
TAATCCGAAC AGGCCCTGGT GGGAAAGATA CCAGCCCATC AGCTACAAGA	TCTGCAGTCG	1920
ATCGGGCAAT GAAAATGAAT TCAGAGACAT GGTGACCAAGA TGCAACAATG	TTGGAGTTCG	1980
TATTTATGTG GATGCTGTTG TCAATCACAT GTGTGGATCT ATGGGTGGCA	CGGGCACCCA	2040

CTCAACATGT GGGAGCTATT TCAACACCGG GACTAGAGAT TTTCCCGCTG TGCCGTACTC	2100
TGCCTGGGAT TTCAATGACG GCAAATGTCA CACTGCAAGT GGAGACATCG AAAATTATGG	2160
GGACATGTAT CAGGTCGGG ATTGCAAGTT GTCCAGCCTT CTTGATCTGG CTCTGGAGAA	2220
GGACTATGTA CGCTCAACAA TTGCAGCGTA CATGAATCAC CTCATTGATA TGGGTGTAGC	2280
AGGGTTCCGG ATCGATGCTG CCAAGCATAT GTGGCCAGGG GACATAAGAG CGTTTCTGGA	2340
CAAACGTGAC GATCTAAATA CTCAGTGGTT TTCAGCAGGA ACGAAACCCCT TTATTTACCA	2400
AGAGGTAATT GACTTGGGAG GAGAGCCAAT CACAGGCAGT CAGTACTTTG GGAATGGCCG	2460
CGTGACAGAA TTCAAGTATG GTGCCAAACT GGGGACGGTG ATCCGGAAGT GGAATGGAGA	2520
GAAGATGGCC TACTTAAAGA ACTGGGGAGA AGGCTGGGC TTTGTGCCCTT CTGACAGAGC	2580
CCTGGTGTGTT GTGGATAACC ACGACAACCA GCGGGGGCAC GGGGCAGGCG GAGCTTCCAT	2640
TCTTACTTTTC TGGGATGCCA GGCTTTATAA AATGGCGGTT GGTTTCATGC TCGCTCATCC	2700
GTACGGGTTTC ACACGGGTGA TGTCAAGTTA TCGTTGGCCA AGATATTTCG AAAACGGAGT	2760
GGATGTTAAC GACTGGGTGG GACCACCAAG TAACTCGGAC GGATCGACGA AGTCCGTTAC	2820
AATCAACGCA GACACTACCT GTGGCAATGA CTGGGTCTGC GAACATCGCT GGCACAAAT	2880
AAGGAACATG GTTATCTTCC GTATGTGGT AGACGGTCAG CCTTTCTCAA ACTGGTGGGA	2940
CAACGGGAGC AATCAAGTAG CTTTCGGTCG CGGCGACAGA GGCTTCATTG TCTTTAATAA	3000
TGATGACTGG TATATGAATG TCGATTGCA AACTGGTCTG CCTGCTGGAA CCTACTGCGA	3060
TGTTATTTCT GGACAAAAGG AAGGCAGTGC GTGTACTGGG AAGCAGGTGT ACGTTTCCTC	3120
GGATGGAAAG GCCAATTTC AGATTAGTAA CAGCGATGAA GATCCATTG TTGCAATTCA	3180
CGTTGATGCC AAGTTATAAG CTTCGAGGAT CCACTAGTAA CGGCCGCCAG TGTGCTGGAA	3240
TTCCGGTTGT CGACATCTAG GGCGGCCAAT TCCGCCCTC TCCCCCCCCC CCCTAACGTT	3300
ACTGGCCGAA GCCGCTTGGG ATAAGGCCGG TGTGTGTTTG TCTATATGTG ATTTTCCACC	3360
ATATTGCCGT CTTTGGCAA TGTGAGGGCC CGGAAACCTG GCCCTGTCTT CTTGACGAGC	3420
ATTCCCTAGGG GTCTTTCCCC TCTCGCCAAA GGAATGCAAG GTCTGTTGAA TGTGCTGAAG	3480
GAAGCAGTTC CTCTGGAAGC TTCTTGAAGA CAAACAAACGT CTGTAGCGAC CCTTTGCAGG	3540
CAGCGGAACC CCCCCACCTGG CGACAGGTGC CTCTGCGGCC AAAAGCCACG TGTATAAGAT	3600
ACACCTGCAA AGGCGGCACA ACCCCAGTGC CACGTTGTGA GTTGGATAGT TGTGAAAGA	3660
GTCAAATGGC TCTCCTCAAG CGTAGTCAAC AAGGGGCTGA AGGATGCCA GAAGGTACCC	3720

CATTGTATGG	GAATCTGATC	TGGGGCCTCG	GTGCACATGC	TTTACATGTG	TTTAGTCGAG	3780
GTTAAAAAAAG	CTCTAGGCC	CCCGAACAC	GGGGACGTGG	TTTCCTTTG	AAAAACACGA	3840
TGATAAGCTT	GCCACAACCC	AAACAGCGTC	AACAGCGTGC	CGCAGATCCC	GGGCAATGAG	3900
ATATGAAAAA	GCCTGAACTC	ACCGCGACGT	CTGTCGAGAA	GTTTCTGATC	GAAAAGTTCG	3960
ACAGCGTCTC	CGACCTGATG	CAGCTCTCGG	AGGGCGAAGA	ATCTCGTGCT	TTCAGCTTCG	4020
ATGTTAGGAGG	GCGTGGATAT	GTCCTGCGGG	TAAATAGCTG	CGCCGATGGT	TTCTACAAAG	4080
ATCGTTATGT	TTATCGGCAC	TTTGCATCGG	CCGCGCTCCC	GATTCCGGAA	GTGCTTGACA	4140
TTGGGGAATT	CAGCGAGAGC	CTGACCTATT	GCATCTCCCG	CCGTGCACAG	GGTGTACAGT	4200
TGCAAGACCT	GCCTGAAACC	GAACTGCCCG	CTGTTCTGCA	GCCGGTCCGG	GAGGCCATGG	4260
ATGCGATCGC	TGCGGCCGAT	CTTAGCCAGA	CGAGCGGGTT	CGGCCCATTC	GGACCGCAAG	4320
GAATCGGTCA	ATACACTACA	TGGCGTGATT	TCATATGCGC	GATTGCTGAT	CCCCATGTGT	4380
ATCACTGGCA	AACTGTGATG	GACGACACCG	TCAGTGCCTC	CGTCGCGCAG	GCTCTCGATG	4440
AGCTGATGCT	TTGGGCCGAG	GACTGCCCG	AAAGTCCGGCA	CCTCGTGCAC	GCGGATTTCG	4500
GCTCCAACAA	TGTCTGACG	GACAATGGCC	GCATAACAGC	GGTCATTGAC	TGGAGCGAGG	4560
CGATGTTCCG	GGATTCCCAA	TACGAGGTCTG	CCAACATCTT	CTTCTGGAGG	CCGTGGTTGG	4620
CTTGTATGGA	GCAGCAGACG	CGCTACTTCG	AGCGGAGGCA	TCCGGAGCTT	GCAGGATCGC	4680
CGCGGCTCCG	GGCGTATATG	CTCCGCATTG	GTCTTGACCA	ACTCTATCAG	AGCTTGGTTG	4740
ACGGCAATT	CGATGATGCA	GCTTGGCGC	AGGGTCGATG	CGACGCAATC	GTCCGATCCG	4800
GAGCCGGGAC	TGTGGCGGT	ACACAAATCG	CCCGCAGAAG	CGCGGCCGTC	TGGACCGATG	4860
GCTGTGTAGA	AGTACTCGCC	GATAGTGGAA	ACCGACGCC	CAGCACTCGT	CCGAGGGCAA	4920
AGGAATAGGG	GAGATGGGGG	AGGCTAACTG	AAACACGGAA	GGGCCCCGG	GACTCTGGGG	4980
TTCGATAAAA	TAAAAGATT	TATTTAGTCT	CCAGAAAAAG	GGGGGAATGA	AAGACCCCAC	5040
CTGTAGGTTT	GGCAAGCTAG	CTTAAGTAAC	GCCATTTCGC	AAGGCATGGA	AAAATACATA	5100
ACTGAGAATA	GAGAAGTTCA	GATCAAGGTC	AGGAACAGAT	GGAACAGCTG	AATATGGGCC	5160
AAACAGGATA	TCTGTGGTAA	GCAGTTCC	CCCCGGCTCA	GGGCCAAGAA	CAGATGGAAC	5220
AGCTGAATAT	GGGCCAAACA	GGATATCTGT	GGTAAGCAGT	TCCTGCCCG	GCTCAGGGCC	5280
AAGAACAGAT	GGTCCCCAGA	TGGGTCCAG	CCCTCAGCAG	TTTCTAGAGA	ACCATCAGAT	5340
GTTCAGGG	TGCCCAAGG	ACCTGAAATG	ACCTGTGCC	TTATTTGAAC	TAACCAATCA	5400

GTTCGCTTCT CGCTTCTGTT CGCGCGCTTC TGCTCCCCGA GCTCAATAAA AGAGCCCACA	5460
ACCCCTCACT CGGGGCGCCA GTCCTCCGAT TGACTGAGTC GCCCGGGTAC CCGTGTATCC	5520
AATAAAACCCT CTTGCAGTTG CATCCGACTT GTGGTCTCGC TGTTCCCTGG GAGGGTCTCC	5580
TCTGAGTGAT TGACTACCCG TCAGCGGGGG TCTTTCATTT GGGGGCTCGT CCGGGATCGG	5640
GAGACCCCTG CCCAGGGACC ACCGACCCAC CACCGGGAGG TAAGCTGGCT GCCTCGCGCG	5700
TTTCGGTGAT GACGGTGAAA ACCTCTGACA CATGCAGCTC CCGGAGACGG TCACAGCTTG	5760
TCTGTAAGCG GATGCCGGGA GCAGACAAAGC CCGTCAGGGC GCGTCAGCGG GTGTTGGCGG	5820
GTGTCGGGGC GCAGCCATGA CCCAGTCACG TAGCGATAGC GGAGTGTATA CTGGCTTAAC	5880
TATGCGGCAT CAGAGCAGAT TGTACTGAGA GTGCACCATA TGCGGTGTGA AATACCGCAC	5940
AGATGCGTAA GGAGAAAATA CCGCATCAGG CGCTCTTCG CTTCCCTCGCT CACTGACTCG	6000
CTGCGCTCGG TCGTTCGGCT GCGGCGAGCG GTATCAGCTC ACTCAAAGGC GGTAATACGG	6060
TTATCCACAG AATCAGGGGA TAACGCAGGA AAGAACATGT GAGCAAAAGG CCAGCAAAAG	6120
GCCAGGAACC GTAAAAAGGC CGCGTTGCTG GCGTTTTTCC ATAGGCTCCG CCCCCCTGAC	6180
GAGCATCACA AAAATCGACG CTCAAGTCAG AGGTGGCGAA ACCCGACAGG ACTATAAAGA	6240
TACCAGGCCT TTCCCCCTGG AAGCTCCCTC GTGCGCTCTC CTGTTCCGAC CCTGCCGCTT	6300
ACCGGATACC TGTCCGCCTT TCTCCCTTCG GGAAGCGTGG CGCTTTCTCA TAGCTCACGC	6360
TGTAGGTATC TCAGTTCGGT GTAGGTGCGTT CGCTCCAAGC TGGGCTGTGT GCACGAACCC	6420
CCCGTTCAAGC CCGACCGCTG CGCCTTATCC GGTAACTATC GTCTTGAGTC CAACCCGGTA	6480
AGACACGACT TATCGCCACT GGCAGCAGCC ACTGGTAACA GGATTAGCAG AGCGAGGTAT	6540
GTAGGCCTG CTACAGAGTT CTTGAAGTGG TGGCCTAACT ACGGCTACAC TAGAAGGACA	6600
GTATTTGGTA TCTGCCCTCT GCTGAAGCCA GTTACCTTCG GAAAAAGAGT TGGTAGCTCT	6660
TGATCCGGCA AACAAACCAC CGCTGGTAGC GGTGGTTTT TTGTTGCAA GCAGCAGATT	6720
ACGGCGAGAA AAAAGGATC TCAAGAAGAT CCTTTGATCT TTTCTACGGG GTCTGACGCT	6780
CAGTGGAACG AAAACTCACG TTAAGGGATT TTGGTCATGA GATTATCAA AAGGATCTTC	6840
ACCTAGATCC TTTAAATTA AAAATGAAGT TTTAAATCAA TCTAAAGTAT ATATGAGTAA	6900
ACTTGGTCTG ACAGTTACCA ATGCTTAATC AGTGAGGCAC CTATCTCAGC GATCTGTCTA	6960
TTTCGTTCAT CCATAGTTGC CTGACTCCCC GTCGTGTAGA TAACTACGAT ACGGGAGGGC	7020
TTACCATCTG GCCCCAGTGC TGCAATGATA CCGCGAGACC CACGCTCACC GGCTCCAGAT	7080

TTATCAGCAA TAAACCAGCC AGCCGGAAGG GCCGAGCGCA GAAGTGGTCC TGCAACTTTA	7140
TCCGCCTCCA TCCAGTCTAT TAATTGTTGC CGGGAAGCTA GAGTAAGTAG TTGCCAGTT	7200
AATAGTTGC GCAACGTTGT TGCCATTGCT GCAGGCATCG TGGTGTACCG CTCGTCGTTT	7260
GGTATGGCTT CATTCAAGCTC CGGTTCCCAA CGATCAAGGC GAGTTACATG ATCCCCCATG	7320
TTGTGCAAAA AAGCGGTTAG CTCCCTCGGT CCTCCGATCG TTGTCAGAAG TAAGTTGGCC	7380
GCAGTGTTAT CACTCATGGT TATGGCAGCA CTGCATAATT CTCTTACTGT CATGCCATCC	7440
GTAAGATGCT TTTCTGTGAC TGGTGAGTAC TCAACCAAGT CATTCTGAGA ATAGTGTATG	7500
CGGCGACCGA GTTGCTCTTG CCCGGCGTCA ACACGGGATA ATACCGCGCC ACATAGCAGA	7560
ACTTTAAAAG TGCTCATCAT TGGAAAACGT TCTTCGGGGC GAAAACCTCTC AAGGATCTTA	7620
CCGCTGTTGA GATCCAGTTC GATGTAACCC ACTCGTGCAC CCAACTGATC TTCAGCATCT	7680
TTTACTTTCA CCAGCGTTTC TGGGTGAGCA AAAACAGGAA GGCAAAATGC CGCAAAAAAG	7740
GGAATAAGGG CGACACGGAA ATGTTGAATA CTCATACTCT TCCCTTTTCA ATATTATTGA	7800
AGCATTATTC AGGGTTATTG TCTCATGAGC GGATACATAT TTGAATGTAT TTAGAAAAAT	7860
AAACAAATAG GGGTCCGCG CACATTTCCC CGAAAAGTGC CACCTGACGT CTAAGAAACC	7920
ATTATTATCA TGACATTAAC CTATAAAAAT AGGCGTATCA CGAGGCCCCCTT TCGTCTTCAA	7980

(2) INFORMATION FOR SEQ ID NO: 3:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7311 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GAATTCTACAC CAGATCACCG AAAACTGTCC TCCAAATGTG TCCCCCTCAC ACTCCCAAAT	60
TCGCGGGCTT CTGCCTCTTA GACCACTCTA CCCTATTCCC CACACTCACC GGAGCCAAAG	120
CCGCGGCCCT TCCGTTTCTT TGCTTTGAA AGACCCACC CGTAGGTGGC AAGCTAGCTT	180
AAGTAACGCC ACTTTGCAAG GCATGGAAAA ATACATAACT GAGAATAGAA AAGTTCAGAT	240
CAAGGTCAGG AACAAAGAAA CAGCTGAATA CCAAACAGGA TATCTGTGGT AAGCGGTTCC	300

TGCCCCGGCT CAGGGCCAAG AACAGATGAG ACAGCTGAGT GATGGGCCAA ACAGGATATC	360
TGTGGTAAGC AGTTCCCTGCC CCGGCTCGGG GCCAAGAACAA GATGGTCCCC AGATGCGGTC	420
CAGCCCTCAG CAGTTTCTAG TGAATCATCA GATGTTCCA GGGTCCCCA AGGACCTGAA	480
AATGACCCCTG TACCTTATTT GAACTAACCA ATCAGTTCGC TTCTCGCTTC TGTCGCGCG	540
CTTCCGCTCT CCGAGCTCAA TAAAAGAGCC CACAACCCCT CACTGGCGC GCCAGTCTTC	600
CGATAGACTG CGTCGCCCCGG GTACCCGTAT TCCCAATAAA GCCTCTTGCT GTTGATC	660
GAATCGTGGT CTCGCTGTT CTTGGGAGGG TCTCCTCTGA GTGATTGACT ACCCACGACG	720
GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA TTTGGAGACC CCTGCCAGG GACCACCGAC	780
CCACCACCGG GAGGTAAGCT GCCAGAAC TTATCTGTGT CTGTCGATT GTCTAGTGT	840
TATGTTGAT GTTATGCGCC TCGTCTGTA CTAGTTAGCT AACTAGCTCT GTATCTGGCG	900
GACCCGTGGT GGAACGTGACG AGTTCTGAAC ACCCGGCCGC AACCTGGGA GACGTCCAG	960
GGACTTTGGG GGCGTTTTT GTGGCCCGAC CTGAGGAAGG GAGTCGATGT GGAATCCGAC	1020
CCCGTCAGGA TATGTGGTTC TGGTAGGAGA CGAGAACCTA AAACAGTTCC CGCCTCCGTC	1080
TGAATTTTG CTTTCGGTTT GGAACCGAAG CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG	1140
CATCGTTCTG TGTGACTGT GTCTGACTGT GTTTCTGTAT TTGTCTGAAA ATTAGGGCCA	1200
GACTGTTACC ACTCCCTTAA GTTTGACCTT AGGTCACTGG AAAGATGTCG AGCGGATCGC	1260
TCACAACCAAG TCGGTAGATG TCAAGAACAGAG ACGTTGGGTT ACCTCTGCT CTGAGAACATG	1320
GCCAACCTTT AACGTGGAT GGCGCGAGA CGGCACCTTT AACCGAGACC TCATCACCA	1380
GGTTAAGATC AAGGTCTTTT CACCTGGCCC GCATGGACAC CCAGACCAGG TCCCCTACAT	1440
CGTGACCTGG GAAGCCTTGG CTTTGACCC CCCTCCCTGG GTCAAGCCCT TTGTACACCC	1500
TAAGCCTCCG CCTCCTCTTC CTCCATCCGC CCCGCTCTC CCCCTGAAC CTCCTCGTTC	1560
GACCCCGCCT CGATCCCTCCC TTTATCCAGC CCTCACTCCT TCTCTAGGCG CCGGAATTCC	1620
GATCTGATCA AGAGACAGGA TGAGGATCGT TTGCGATGAT TGAACAAGAT GGATTGCACG	1680
CAGGTTCTCC GGCGCTTGG GTGGAGAGGC TATTCGGCTA TGACTGGCA CAACAGACAA	1740
TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGA GGGGCGCCCG GTTCTTTTG	1800
TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT	1860
GGCTGGCCAC GACGGCGTT CCTTGCGCAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA	1920
GGGACTGGCT GCTATTGGGC GAAGTGCCGG GGCAGGATCT CCTGTCATCT CACCTTGCTC	1980

CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG	2040
CTACCTGCCCT ATTGACCCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG	2100
AAGCCGGTCT TGTCGATCAG GATGATCTGG ACGAAGAGCA TCAGGGGCTC GCGCCAGCCG	2160
AACTGTTCCG CAGGCTCAAG GCGCGCATGC CCGACGGCGA GGATCTCGTC GTGACCCATG	2220
GCGATGCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTTCTGGA TTCATCGACT	2280
GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC CGTGATATTG	2340
CTGAAGAGCT TGGCGCGAA TGGGCTGACC GCTTCCTCGT GCTTTACGGT ATCGCCGCTC	2400
CCGATTTCGCA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTTCTGA GCAGGGACTCT	2460
GGGGTTCGAA ATGACCGACC AAGCGACGCC CAACCTGCCA TCACGAGATT TCGATTCCAC	2520
CGCCGCCTTC TATGAAAGGT TGGGCTTCGG AATCGTTTC CGGGACGCCG GCTGGATGAT	2580
CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCAC CCCGGGCTCG ATCCCCTCGC	2640
GAGTTGGTTC AGCTGCTGCC TGAGGCTGGA CGACCTCGCG GAGTTCTACC GGCAGTGCAA	2700
ATCCGTCGGC ATCCAGGAAA CCAGCAGCGG CTATCCGCGC ATCCATGCC CCGAACTGCA	2760
GGAGTGGGGA GGCACGATGG CCGCTTTGGT CGAGGCGGAT CCGGGCAGAA ATGGTTGAAC	2820
TCCCCGAGAGT GTCCTACACC TAGGGGAGAA GCAGCCAAGG GGTTGTTCC CACCAAGGAC	2880
GACCCGTCTG CGCACAAACG GATGAGCCCA TCAGACAAAG ACATATTCA TCTCTGCTGC	2940
AAACTTGGCA TAGCTCTGCT TTGCCTGGGG CTATTGGGG AAGTTGCGGT TCGTGCTCGC	3000
AGGGCTCTCA CCCTTGACTC TTTTAATAGC TCTTCTGTGC AAGATTACAA TCTAAACAAT	3060
TCGGAGAACT CGACCTTCCT CCTGAGGCCA GGACCACAGC CAACTTCCTC TTACAAGCCG	3120
CATCGATTTC GTCCTTCAGA AATAGAAATA AGAATGCTTG CTAAAAATTA TATTTTTTAC	3180
AATAAGACCA ATCCAATAGG TAGATTATTA GTTACTATGT TAAGAAATGA ATCATTATCT	3240
TTTAGTACTA TTTTTACTCA AATTCAAGAAG TTAGAAATGG GAATAGAAAA TAGAAAGAGA	3300
CGCTCAACCT CAATTGAAGA ACAGGTGCAGA GGACTATTGA CCACAGGCCT AGAAAGTAAAA	3360
AAGGGAAAAAA AGAGTGGGGT TGTCAAAATA GGAGACAGGT GGTGGCAACC AGGGACTTAT	3420
AGGGGACCTT ACATCTACAG ACCAACAGAT GCCCCCTTAC CATATACAGG AAGATATGAC	3480
TTAAATTGGG ATAGGTGGGT TACAGTCAAT GGCTATAAAG TGTTATATAG ATCCCTCCCT	3540
TTTCGTGAAA GACTGCCAG AGCTAGACCT CCTTGGTGTGTA TGTTGTCTCA AGAAGAAAAA	3600
GACGACATGA AACAAACAGGT ACATGATTAT ATTTATCTAG GAACAGGAAT GCACCTTTGG	3660

GGAAAGATTT	TCCATACCAA	GGAGGGGACA	GTGGCTGGAC	TAATAGAAC	TTATTCTGCA	3720
AAAACTCATG	GCATGAGTTA	TTATGAATAG	CCTTTATTGG	CCCAACCTTG	CGGTTCCAG	3780
GGCTTAAGTA	AGTTTTGGT	TACAAACTGT	TCTTAAAACG	AGGATGTGAG	ACAAGTGGTT	3840
TCCTGACTTG	GTGTTGGTATC	AAAGGTTCTG	ATCTGAGCTC	TGAGTGTCT	ATTTTCCTAT	3900
GTTCTTTGG	AATTATCCA	AATCTTATGT	AAATGCTTAT	GTAAACCAAG	ATATAAAAGA	3960
GTGCTGATTT	TTTGAGTAAA	CTTGCAACAG	TCCTAACATT	CACCTCTTGT	GTGTTTGTGT	4020
CTGTTCGCCA	TCCCCTCTCC	GCTCGTCACT	TATCCTTCAC	TTTCCAGAGG	GTCCCCCGC	4080
AGACCCCCGGC	GACCCCTCAGG	TCGGCCGACT	GCGGCAGCTG	GCGCCCGAAC	AGGGACCCCTC	4140
GGATAAGTGA	CCCTTGTCTC	TATTTCTACT	ATTTGGTGT	TGTCTTGTAT	TGTCTCTTTC	4200
TTGTCGGCT	ATCATCACAA	GAGCGGAACG	GACTCACCAT	AGGGACCAAG	CTTGTGACA	4260
TTTCTGCAGA	TATCCATCAC	ACTGGCGGCC	GCTCGAGCAT	GCATCTAGAA	CATCGATAAA	4320
ATAAAAGATT	TTATTTAGTC	TCCAGAAAAA	GGGGGAAATG	AAAGACCCCA	CCTGTAGGTT	4380
TGGCAAGCTA	GCTTAAGTAA	CGCCATTGG	CAAGGCATGG	AAAAATACAT	AACTGAGAAT	4440
AGAGAAGTTC	AGATCAAGGT	CAGGAACAGA	TGGAACAGCT	GAATATGGC	CAAACAGGAT	4500
ATCTGTGGTA	AGCAGTTCT	GCCCCGGCTC	AGGGCCAAGA	ACAGATGGAA	CAGCTGAATA	4560
TGGGCCAAAC	AGGATATCTG	TGGTAAGCAG	TTCTGCCCC	GGCTCAGGGC	CAAGAACAGA	4620
TGGTCCCCAG	ATGCGGTCCA	GCCCTCAGCA	GTGTTCTAGAG	AACCATCAGA	TGTTTCCAGG	4680
GTGCCCCAAG	GACCTGAAAT	GACCCGTGTC	CTTATTTGAA	CTAACCAATC	AGTCGCTTC	4740
TCGCTTCTGT	TCGCGCGCTT	CTGCTCCCCG	AGCTCAATAA	AAGAGCCCAC	AACCCCTCAC	4800
TCGGGGCGCC	AGTCCTCCGA	TTGACTGAGT	CGCCCGGGTA	CCCGTGTATC	CAATAAACCC	4860
TCTTGCAGTT	GCATCCGACT	TGTGGTCTCG	CTGTTCTTG	GGAGGGTCTC	CTCTGAGTGA	4920
TTGACTACCC	GTCAGCGGGG	GTCTTTCATT	TGGGGCTCG	TCCGGGATCG	GGAGACCCCT	4980
GCCCAGGGAC	CACCGACCCA	CCACCGGGAG	GTAAGCTGGC	TGCCTCGCG	GTTCGGTGA	5040
TGACGGTGAA	AACCTCTGAC	ACATGCAGCT	CCCGGAGACG	GTCACAGCTT	GTCTGTAAGC	5100
GGATGCCGGG	AGCAGACAAG	CCCGTCAGGG	CGCGTCAGCG	GGTGTGGCG	GGTGTGGGG	5160
CGCAGCCATG	ACCCAGTCAC	GTAGCGATAG	CGGAGTGTAT	ACTGGCTTAA	CTATGCGGCA	5220
TCAGAGCAGA	TTGTACTGAG	AGTGCACCAT	ATGCGGTGTG	AAATACCGCA	CAGATGGTA	5280
AGGAGAAAAT	ACCGCATCAG	GCGCTCTTCC	GCTTCCTCGC	TCACTGACTC	GCTGCGCTCG	5340

GTCGTTCGGC	TGCGGGGAGC	GGTATCAGCT	CACTCAAAGG	CGGTAATACG	GTTATCCACA	5400
GAATCAGGGG	ATAACGCAGG	AAAGAACATG	TGAGCAAAAG	GCCAGCAAA	GGCCAGGAAC	5460
CGTAAAAAGG	CCGCCTTGCT	GGCGTTTTTC	CATAGGCTCC	GCCCCCTGA	CGAGCCTCAC	5520
AAAAATCGAC	GCTCAAGTCA	GAGGTGGCGA	AACCCGACAG	GACTATAAG	ATACCAGGCG	5580
TTTCCCCCTG	GAAGCTCCCT	CGTGCCTCT	CCTGTTCCGA	CCCTGCCGCT	TACCGGATAC	5640
CTGTCCGCCT	TTCTCCCTTC	GGGAAGCGTG	GCGCTTCTC	ATAGCTCACG	CTGTAGGTAT	5700
CTCAGTTCGG	TGTAGGTCGT	TCGCTCCAAG	CTGGGCTGTG	TGCAAGAAC	CCCCGTTCA	5760
CCCGACCGCT	GCGCCTTATC	CGGTAACTAT	CGTCTTGAGT	CCAACCCGGT	AAGACACGAC	5820
TTATGCCAC	TGGCAGCAGC	CACTGGTAAC	AGGATTAGCA	GAGCGAGGTA	TGTAGGCGGT	5880
GCTACAGAGT	TCTTGAAGTG	GTGGCCTAAC	TACGGCTACA	CTAGAAGGAC	AGTATTTGGT	5940
ATCTGCGCTC	TGCTGAAGCC	AGTTACCTTC	GGAAAAAGAG	TTGGTAGCTC	TTGATCCGGC	6000
AAACAAACCA	CCGCTGGTAG	CGGTGGTTTT	TTTGTGCA	AGCAGCAGAT	TACGCGCAGA	6060
AAAAAAGGAT	CTCAAGAAGA	TCCTTGTATC	TTTCTACGG	GGTCTGACGC	TCAGTGGAAC	6120
GAAAACTCAC	GTTAAGGGAT	TTGGTCATG	AGATTATCAA	AAAGGATCTT	CACCTAGATC	6180
CTTTAAATT	AAAAATGAAG	TTTAAATCA	ATCTAAAGTA	TATATGAGTA	AACTTGGTCT	6240
GACAGTTACC	AATGCTTAAT	CAGTGAGGCA	CCTATCTCAG	CGATCTGTCT	ATTCGTTCA	6300
TCCATAGTTG	CCTGACTCCC	CGTCGTGTAG	ATAACTACGA	TACGGGAGGG	CTTACCATCT	6360
GGCCCCAGTG	CTGCAATGAT	ACCGCGAGAC	CCACGCTCAC	CGGCTCCAGA	TTTATCAGCA	6420
ATAAACCAGC	CAGCCGGAAG	GGCCGAGCGC	AGAAGTGGTC	CTGCAACTTT	ATCCGCTCC	6480
ATCCAGTCTA	TTAATTGTTG	CCGGGAAGCT	AGAGTAAGTA	GTTCGCCAGT	TAATAGTTG	6540
CGCAACGTTG	TTGCCATTGTC	TGCAGGCATC	GTGGTGTAC	GCTCGTCGTT	TGGTATGGCT	6600
TCATTTCAGCT	CCGGTTCCCA	ACGATCAAGG	CGAGTTACAT	GATCCCCAT	GTTGTGCAA	6660
AAAGCGGTTA	GCTCCTTCGG	TCCTCCGATC	GTTCAGAA	GTAAGTGGC	CGCACTGTTA	6720
TCACTCATGG	TTATGGCAGC	ACTGCATAAT	TCTCTTACTG	TCATGCCATC	CGTAAGATGC	6780
TTTCTGTGA	CTGGTGAGTA	CTCAACCAAG	TCATTCTGAG	AAATAGTGTAT	GCGCGACCG	6840
AGTTGCTCTT	GCCCCGGCCTC	AACACGGGAT	AATACCGCGC	CACATAGCAG	AACTTTAAA	6900
GTCGCTCATCA	TTGGAAAACG	TTCTTCGGGG	CGAAAACCTCT	CAAGGATCTT	ACCGCTGTTG	6960
AGATCCAGTT	CGATGTAACC	CACTCGTGCA	CCCAACTGAT	CTTCAGCCTAC	TTTTACTTTC	7020

ACCAGCGTTT CTGGGTGAGC AAAAACAGGA AGGCATAATG CCGCAAAAAA GGGAAATAAGG	7080
GCGACACGGA AATGTTGAAT ACTCATACTC TTCCCTTTTC AATATTATTG AAGCATTAT	7140
CAGGGTTATT GTCTCATGAG CGGATACATA TTTGAATGTA TTTAGAAAAA TAAACAAATA	7200
GGGGTTCCGC GCACATTTCC CCGAAAAGTG CCACCTGACG TCTAAGAAC CATTATTATC	7260
ATGACATTAA CCTATAAAAAA TAGGCGTATC ACGAGGCCCT TTCTGCTTCA A	7311

(2) INFORMATION FOR SEQ ID NO: 4:

- (i) SEQUENCE CHARACTERISTICS:
- (A) LENGTH: 7885 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: circular

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

GAATTCTACAC CAGATCACCG AAAACTGTCC TCCAAATGTG TCCCCCTCAC ACTCCAAAT	60
TCGCAGGGCTT CTGCCTCTTA GACCACTCTA CCCTATTCCC CACACTCACC GGAGCCAAAG	120
CCGCAGGCCCT TCCGTTTCTT TGCTTTGAA AGACCCCACC CGTAGGTGGC AAGCTAGCTT	180
AAGTAACGCC ACTTTGCAAG GCATGGAAAA ATACATAACT GAGAATAGAA AAGTCAGAT	240
CAAGGTCAGG AACAAAGAAA CAGCTGAATA CCAACAGGA TATCTGTGGT AAGCGGTTC	300
TGCCCCGGCT CAGGGCCAAG AACAGATGAG ACAGCTGAGT GATGGGCCAA ACAGGATATC	360
TGTGGTAAGC AGTTCTGCC CCGGCTCGGG GCCAAGAACCA GATGGTCCCC AGATGGGTC	420
CAGCCCTCAG CAGTTCTAG TGAATCATCA GATGTTCCA GGGTGCCCCA AGGACCTGAA	480
AATGACCTCTG TACCTTATTT GAACTAACCA ATCAGTTCGC TTCTCGCTTC TGTTGGCG	540
CTTCCGCTCT CCGAGCTCAA TAAAAGAGCC CACAACCCCT CACTCGCGC GCCAGCTTC	600
CGATAGACTG CGTCGCCCGG GTACCCGTAT TCCCAATAAA GCCTCTTGCT GTTGCAATCC	660
GAATCGTGGT CTCGCTGTT CTTGGGAGGG TCTCCTCTGA GTGATTGACT ACCCACGACG	720
GGGGTCTTTC ATTTGGGGGC TCGTCCGGGA TTTGGAGACC CCTGCCAGG GACCACCGAC	780
CCACCACCGG GAGGTAAGCT GGCCAGAAC TTATCTGTGT CTGTCCGATT GTCTAGTGT	840
TATGTTTGAT GTTATGGGCC TGGCTCTGTA CTAGTTAGCT AACTAGCTCT GTATCTGGCG	900
GACCCGTGGT GGAACTGACG AGTTCTGAAC ACCCGGCCGC AACCTGGGA GACGTCCCAG	960

GGACTTTGGG GGCGTTTT GTGGCCGAC CTGAGGAAGG GAGTCGATGT GGAATCCGAC	1020
CCCGTCAGGA TATGTGGTTC TGGTAGGAGA CGAGAACCTA AAACAGTTCC CGCCTCCGTC	1080
TGAATTTTG CTTTCGGTTT GGAACCGAAG CCGCGCGTCT TGTCTGCTGC AGCGCTGCAG	1140
CATCGTTCTG TGTTGTCTCT GTCTGACTGT GTTTCTGTAT TTGTCTGAAA ATTAGGGCCA	1200
GAATGTTACC ACTCCCTTAA GTTGACCTT AGGTCACTGG AAAGATGTGC AGCGGATCGC	1260
TCACAAACAG TCGGTAGATG TCAAGAAGAG ACGTTGGGTT ACCTTCTGCT CTGCAGAATG	1320
GCCAACCTTT AACGTCGGAT GGCGCGAGA CGGCACCTTT AACCGAGACC TCATCACCCA	1380
GGTTAAGATC AAGGTCTTTT CACCTGGCCC GCATGGACAC CCAGACCAGG TCCCCTACAT	1440
CGTGACCTGG GAAGCCTTGG CTTTGACCC CCCTCCCTGG GTCAAGCCCT TTGTACACCC	1500
TAAGCCTCCG CCTCCTCTTC CTCCATCCGC CCCGTCTCTC CCCCTTGAAC CTCCTCGTTC	1560
GACCCCGCCT CGATCCCTCCC TTTATCCAGC CCTCACTCCT TCTCTAGGCG CGGAATTCC	1620
GATCTGATCA AGAGACAGGA TGAGGATCGT TTGCGATGAT TGAACAAGAT GGATTGCACG	1680
CAGGTTCTCC GGCGCTTGG GTGGAGAGGC TATTGGCTA TGACTGGCA CAACAGACAA	1740
TCGGCTGCTC TGATGCCGCC GTGTTCCGGC TGTCAGCGCA GGGGCGCCCG GTTCTTTTG	1800
TCAAGACCGA CCTGTCCGGT GCCCTGAATG AACTGCAGGA CGAGGCAGCG CGGCTATCGT	1860
GGCTGGCCAC GACGGCGTT CCTTGGCGAG CTGTGCTCGA CGTTGTCACT GAAGCGGGAA	1920
GGGACTGGCT GCTATTGGGC GAAAGTGCCGG GGCAGGATCT CCTGTCACTCT CACCTTGCTC	1980
CTGCCGAGAA AGTATCCATC ATGGCTGATG CAATGCGGCG GCTGCATACG CTTGATCCGG	2040
CTACCTGCCCT ATTGACCCAC CAAGCGAAAC ATCGCATCGA GCGAGCACGT ACTCGGATGG	2100
AAGCCGGTCT TGTCGATCAG GATGATCTGG ACGAAGAGCA TCAGGGCTC GCGCCAGCCG	2160
AACTGTTCGC CAGGCTCAAG GCGCGCATGC CCGACGGCGA GGATCTCGTC GTGACCCATG	2220
GCGATGCCCTG CTTGCCGAAT ATCATGGTGG AAAATGGCCG CTTTCTGGA TTCATCGACT	2280
GTGGCCGGCT GGGTGTGGCG GACCGCTATC AGGACATAGC GTTGGCTACC CGTGATATTG	2340
CTGAAGAGCT TGGCGGCAGA TGGGCTGACC GCTTCCTCGT GCTTTACGGT ATCGCCGCTC	2400
CCGATTGCGA GCGCATCGCC TTCTATCGCC TTCTTGACGA GTTCTCTGA GCGGGACTCT	2460
GGGGTTCGAA ATGACCGACC AAGCGACGCC CAACCTGCCA TCACGAGATT TCGATTCCAC	2520
CGCCGCCTTC TATGAAAGGT TGGGCTTCGG AATCGTTTTC CGGGACGCCG GCTGGATGAT	2580
CCTCCAGCGC GGGGATCTCA TGCTGGAGTT CTTCGCCAC CCCGGGCTCG ATCCCCTCGC	2640

GAGTTGGTTTC AGCTGCTGCC TGAGGGCTGGA CGACCTCGCG GAGTTCTACC GGCAGTGCAA	2700
ATCCGTCGGC ATCCAGGAAA CCAGCAGCGG CTATCCGCGC ATCCATGCC CCGAACTGCA	2760
GGAGTGCGGA GGCACCGATGG CCGCTTTGGT CGAGGCGGAT CCGGGCAGAA ATGGTTGAAC	2820
TCCCGAGAGT GTCCTACACC TAGGGGAGAA GCAGCCAAGG GGTTGTTCC CACCAAGGAC	2880
GACCCGTCTG CGCACAAACG GATGAGCCCA TCAGACAAAG ACATATTCA TCTCTGCTGC	2940
AAACTTGGCA TAGCTCTGCT TTGCCTGGGG CTATTGGGG AAGTTGCGGT TCGTGCTCGC	3000
AGGGCTCTCA CCCTTGACTC TTTTAATAGC TCTTCTGTGC AAGATTACAA TCTAAACAAT	3060
TCGGAGAACT CGACCTTCCT CCTGAGGCAA GGACCACAGC CAACTTCCTC TTACAAGCCG	3120
CATCGATTTT GTCCTTCAGA AATAGAAATA AGAATGCTTG CTAAAAATTAA TATTTTACCC	3180
AATAAGACCA ATCCAATAGG TAGATTATTA GTTACTATGT TAAGAAATGA ATCATTATCT	3240
TTTAGTACTA TTTTACTCA AATTCAAGAG TTAGAAATGG GAATAGAAAA TAGAAAGAGA	3300
CGCTCAACCT CAATTGAAGA ACAGGTGCAA GGACTATTGA CCACAGGCCT AGAAGTAAAA	3360
AAGGGAAAAA AGAGTGTGTT TGTCAAAATA GGAGACAGGT GGTGGCAACC AGGGACTTAT	3420
AGGGGACCTT ACATCTACAG ACCAACAGAT GCCCCCTTAC CATATACAGG AAGATATGAC	3480
TTAAATTGGG ATAGGTGGGT TACAGTCAAT GGCTATAAAG TGTTATATAG ATCCCTCCCT	3540
TTTCGTGAAA GACTGCCAG AGCTAGACCT CCTTGGTGTGTA TGTTGTCTCA AGAAGAAAAA	3600
GACGACATGA AACAACAGGT ACATGATTAT ATTTATCTAG GAACAGGAAT GCACTTTG	3660
GGAAAGATTG TCCATACCAA GGAGGGACA GTGGCTGGAC TAATAGAACAA TTATTCTGCA	3720
AAAACTCATG GCATGAGTTA TTATGAATAG CCTTTATTGG CCCAACCTTG CGGTTCCCAG	3780
GGCTTAAGTA AGTTTTGGT TACAAACTGT TCTTAAACG AGGATGTGAG ACAAGTGGTT	3840
TCCTGACTTG GTTTGGTATC AAAGGTTCTG ATCTGAGCTC TGAGTGTCT ATTTTCTAT	3900
GTTCTTTGG AATTATCCA AATCTTATGT AAATGCTTAT GTAAACCAAG ATATAAAAGA	3960
GTGCTGATTG TTTGAGTAAA CTTGCAACAG TCCTAACATT CACCTCTTGT GTGTTGTGT	4020
CTGTTGCCA TCCCCTCTCC GCTCGTCACT TATCCTTCAC TTTCCAGAGG GTCCCCCGC	4080
AGACCCCCGGC GACCCCTCAGG TCGGCCGACT GCGGCAGCTG GCGCCCGAAC AGGGACCCCTC	4140
GGATAAGTGA CCCTTGTCTC TATTTCTACT ATTTGGTGTGTT TGTCTTGTAT TGTCTCTTC	4200
TTGTCTGGCT ATCATCACAA GAGCGGAACG GACTCACCAT AGGGACCAAG CTTGTCGACA	4260
TCTAGGGCGG CCAATTCCGC CCCTCTCCCT CCCCCCCCCC TAACGTTACT GGCGAAGCC	4320

GCTTGGAAATA	AGGCCGGTGT	GCGTTTGTCT	ATATGTGATT	TTCCACCATA	TTGCCGTCTT	4380
TTGGCAATGT	GAGGGCCCGG	AAACCTGGCC	CTGTCTTCTT	GACGAGCATT	CCTAGGGTC	4440
TTTCCCCCTCT	CGCCAAAGGA	ATGCAAGGTC	TGTTGAATGT	CGTGAAGGAA	GCAGTTCTC	4500
TGGAAGCTTC	TTGAAGACAA	ACAAACGTCTG	TAGCGACCT	TTGCAGGCAG	CGGAACCCCC	4560
CACCTGGCGA	CAGGTGCCTC	TGCGGCCAAA	AGCCACGTGT	ATAAGATACA	CCTGCAAAGG	4620
CGGCACAACC	CCAGTGCCAC	GTTGTGAGTT	GGATAGTTGT	GGAAAGAGTC	AAATGGCTCT	4680
CCTCAAGCGT	ATTCAACAAG	GGGCTGAAGG	ATGCCAGAAA	GGTACCCCAT	TGTATGGGAT	4740
CTGATCTGGG	GCCTCGGTGC	ACATGCTTTA	CATGTGTTA	GTCGAGGTTA	AAAAAACGTC	4800
TAGGCCCCCC	GAACCACGGG	GACGTGGTTT	TCCTTGAAA	AACACGCCAA	TAATATGGC	4860
GGCCGCTCGA	GCATGCATCT	AGAACATCGA	TAAAATAAAA	GATTTATTT	AGTCTCCAGA	4920
AAAAGGGGGG	AATGAAAGAC	CCCACCTGTA	GGTTTGGCAA	GCTAGCTTAA	GTAAACGCCAT	4980
TTTGCAAGGC	ATGGAAAAAT	ACATAACTGA	GAATAGAGAA	GTTCAGATCA	AGGTCAAGGAA	5040
CAGATGGAAC	AGCTGAATAT	GGGCCAAACA	GGATATCTGT	GGTAAGCAGT	TCCTGCCCG	5100
GCTCAGGGCC	AAGAACAGAT	GGAACAGCTG	AATATGGGCC	AAACAGGATA	TCTGTGGTAA	5160
GCAGTTCTG	CCCCGGCTCA	GGGCCAAGAA	CAGATGGTCC	CCAGATGCGG	TCCAGCCCTC	5220
AGCAGTTCT	AGAGAACCAT	CAGATGTTTC	CAGGGTGCCTC	CAAGGACCTG	AAATGACCCCT	5280
GTGCCTTATT	TGAACTAACCC	AATCAGTTCG	CTTCTCGCTT	CTGTTCGCGC	GCTTCTGCTC	5340
CCCGAGCTCA	ATAAAAGAGC	CCACAACCCC	TCACTCGGGG	CGCCAGTCCT	CCGATTGACT	5400
GAGTCGCCCG	GGTACCCGTG	TATCCAATAA	ACCCCTTTGC	AGTTGCATCC	GACTTGTGGT	5460
CTCGCTGTT	CTTGGGAGGG	TCTCCTCTGA	GTGATTGACT	ACCCGTCAGC	GGGGGTCTTT	5520
CATTTGGGGG	CTCGTCCGGG	ATCGGGAGAC	CCCTGCCAG	GGACCACCGA	CCCACCAACCG	5580
GGAGGTAAGC	TGGCTGCCCTC	GCGCGTTCG	GTGATGACGG	TGAAAACCTC	TGACACATGC	5640
AGCTCCCGGA	GACGGTCACA	GCTTGTCTGT	AAGCGGATGC	CGGGAGCAGA	CAAGCCCGTC	5700
AGGGCGCGTC	AGCGGGTGTT	GGCGGGTGTC	GGGGCGCAGC	CATGACCCAG	TCACGTAGCG	5760
ATAGCGGAGT	GTATACTGGC	TTAACTATGC	GGCATCAGAG	CAGATTGTAC	TGAGAGTGCA	5820
CCATATGCGG	TGTGAAATAC	CGCACAGATG	CGTAAGGAGA	AAATACCGCA	TCAGGGCCTC	5880
TTCCGCTTCC	TCGCTCACTG	ACTCGCTGCG	CTCGGTGTT	CGGCTGCCGC	GAGCGGTATC	5940
AGCTCACTCA	AAGGCGGTAA	TACGGTTATC	CACAGAATCA	GGGGATAACG	CAGGAAAGAA	6000

CATGTGAGCA AAAGGCCAGC AAAAGGCCAG GAACCGTAAA AAGGCCGCGT TGCTGGCGTT	6060
TTTCCATAGG CTCCGCCCCC CTGACGAGCA TCACAAAAAT CGACGCTCAA GTCAGAGGTG	6120
GCGAAACCCG ACAGGACTAT AAAGATACCA GGCGTTTCCC CCTGGAAAGCT CCCTCGTGCG	6180
CTCTCCTGTT CCGACCCCTGC CGCTTACCGG ATACCTGTCC GCCTTCTCC CTTGGGAAG	6240
CGTGGCGCTT TCTCATAGCT CACGCTGTAG GTATCTCAGT TCGGTGTAGG TCGTTCGCTC	6300
CAAGCTGGC TGTGTGCACG AACCCCCCGT TCAGCCGAC CGCTGCGCCT TATCCGGTAA	6360
CTATCGTCTT GAGTCCAACC CGGTAAGACA CGACTTATCG CCACTGGCAG CAGCCACTGG	6420
TAACAGGATT AGCAGAGCGA GGTATGTAGG CGGTGCTACA GAGTTCTTGA AGTGGTGGCC	6480
TAACTACGGC TACACTAGAA GGACAGTATT TGGTATCTGC GCTCTGCTGA AGCCAGTTAC	6540
CTTCGGAAAA AGAGTTGGTA GCTCTTGATC CGGCAAACAA ACCACCGCTG GTAGCGGTGG	6600
TTTTTTGTT TGCAAGCAGC AGATTACGCG CAGAAAAAAA GGATCTCAAG AAGATCCTTT	6660
GATCTTTCT ACGGGGTCTG ACGCTCAGTG GAACGAAAAC TCACGTTAAG GGATTTGGT	6720
CATGAGATTA TCAAAAAGGA TCTTCACCTA GATCCTTTA AATTAAAAAT GAAGTTTTAA	6780
ATCAATCTAA AGTATATATG AGTAAACTTG GTCTGACAGT TACCAATGCT TAATCAGTGA	6840
GGCACCTATC TCAGCGATCT GTCTATTTCG TTTCATCCATA GTTGCCTGAC TCCCCGTG	6900
GTAGATAACT ACGATAACGGG AGGGCTTACC ATCTGGCCCC AGTGCTGCAA TGATACCGCG	6960
AGACCCACGC TCACCGGCTC CAGATTATC AGCAATAAAC CAGCCAGCCG GAAGGGCCGA	7020
GCGCAGAAGT GGTCTTGCAA CTTTATCCGC CTCCATCCAG TCTATTAAATT GTTGCCTGGGA	7080
AGCTAGAGTA AGTAGTTCGC CAGTTAATAG TTTGCGAAC GTTGTGCCA TTGCTGCAGG	7140
CATCGTGGTG TCACGCTCGT CGTTTGGTAT GGCTTCATTG AGCTCCGGTT CCCAACGATC	7200
AAGGCGAGTT ACATGATCCC CCATGTTGTG CAAAAAAAGCG GTTACGCTCCT TCGGTCTCC	7260
GATCGTTGTC AGAAGTAAGT TGGCCGCAGT GTTATCACTC ATGGTTATGG CAGCACTGCA	7320
TAATTCTCTT ACTGTATGCACTC CATCCGTAAG ATGCTTTCT GTGACTGGTG AGTACTCAAC	7380
CAAGTCATTG TGAGAAATAGT GTATGCGCG ACCGAGTTGC TCTTGCCCGG CGTCAACACG	7440
GGATAATACC GCGCCACATA GCAGAACTTT AAAAGTGCTC ATCATTGGAA AACGTTCTTC	7500
GGGGCGAAAA CTCTCAAGGA TCTTAACGCT GTTGAGATCC AGTTCGATGT AACCCACTCG	7560
TGCACCCAAAC TGATCTTCAG CATCTTTAC TTTCACCCAGC GTTCTGGGT GAGCAAAAC	7620
AGGAAGGCAA AATGCCGCAA AAAAGGAAAT AAGGGCGACA CGGAAATGTT GAATACTCAT	7680

45

ACTCTTCCTT TTTCAATATT ATTGAAGCAT TTATCAGGGT TATTGTCTCA TGAGCGGATA	7740
CATATTTGAA TGTATTAGA AAAATAAACCA AATAGGGGTT CCGCGCACAT TTCCCCGAAA	7800
AGTGCCACCT GACGTCTAAG AAACCATTAT TATCATGACA TTAACCTATA AAAATAGGCG	7860
TATCACGAGG CCCTTCGTC TTCAA	7885

THE EMBODIMENTS OF THE INVENTION IN WHICH AN EXCLUSIVE PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS FOLLOWS:

- 1) A method of producing a trans-somatic mammal, wherein said method provides the incorporation of a DNA sequence into the secretory cells of the mammary gland to alter the composition of the milk, wherein said method comprising the steps of:
 - a) providing a vector containing a DNA sequence encoding a valuable compound;
 - b) packaging said vector into a cell line;
 - c) preparing a solution comprising the packaged vector and cell line producing said packaged vector; and
 - d) delivering said solution into the mammary gland to allow the incorporation of the DNA into the secretory cells of the mammary gland.
- 2) The method of Claim 1, wherein the method further comprises the step of flushing the mammary gland with an osmotically-balanced solution prior to delivering the said solution into the mammary gland.
- 3) The method of Claim 2, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.
- 4) The method of Claim 2, wherein the method further comprises the step of growing the cells producing said packaged vector on a solid support means, and the solution comprises the cells on said support means and the packaged vector.
- 5) The method of Claim 4, wherein the method further comprises the step of externally massaging the mammary gland several times a day after delivering the said solution into the mammary gland.
- 6) The method of Claim 2 or 4, wherein a substance, with a density higher than the density

of the solution, is delivered into the mammary gland after the delivery of the solution, wherein said substance displaces the solution upwards in the mammary gland.

- 7) The method of Claim 1, wherein the valuable compound is a pharmaceutical.
- 8) The method of Claim 7, wherein the pharmaceutical is a compound selected from the group consisting of: a tissue plasminogen activator, an antibody, an antibiotic, a blood clotting factor, galactosyltransferase, a growth factor, an oncoprotein, a hormone, a milk protein, a hormone receptor, a tumor suppressor protein, a vaccine and an erythropoietin.
- 9) The method of Claim 8, wherein the pharmaceutical is a tissue plasminogen activator.
- 10) The method of Claim 1, wherein the vector is transiently transfected into PA317 cells; the resulting particles are harvested and trans-infected into PG13 cells.
- 11) The method of Claim 1, wherein the vector is selected from the group pL(X)SH, pL(X)SN, pLNS(X), pLHS(X), pLNC(X), pLHC(X), pLNA(X) and pLHA(X); wherein "A" is the beta actin promoter, "L" is the moloney murine virus long terminal repeat (LTR), "S" is the SV40 promoter, "C" is the cytomegalovirus promoter and "X" is a DNA sequence encoding a valuable compound.
- 12) The method of Claim 1, wherein the vector is selected from the group consisting of pL(X)iN and pL(X)iH; wherein "I" is an internal ribosomal entry site (IRES) and "X" is a DNA sequence encoding a valuable compound.
- 13) The method of Claim 1, wherein the vector is pLN M(X); wherein "M" is a mouse mammary tumor virus promoter and "X" is a DNA sequence encoding a valuable compound.
- 14) The method of Claim 1, wherein the vector is pLN M₂(X); wherein "M" is a mouse mammary tumor virus promoter, "i₂" is a modified wild type internal ribosomal entry site and "X" is a DNA sequence encoding a valuable compound.

15) The method of Claims 11 to 14, wherein "X" is a DNA sequence encoding a tissue plasminogen activator.

16) The method of Claim 1, wherein the solution is an aqueous solution.

17) The method of Claim 2, wherein the osmotically-balanced solution is a saline solution.

18) The method of Claim 4, wherein the solid support means is a matrix selected from the group consisting of Cytodex beads or Cultisphere.

19) The method of Claim 6, wherein said substance is a silicone substance.

20) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a non-retroviral derived particle.

21) The method of Claim 1, wherein the vector is transfected into a packaging cell line producing a retroviral derived particle.

22) The method of Claim 1, wherein the trans-infecting particle is produced *in vitro*.

23) The method of Claim 1, wherein the trans-infecting particle is produced *in vivo*.

1/2




FIG. 1

2/2




FIG. 2

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/00607

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/00 A01K67/027 C12N15/86 C12N9/72

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A01K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	ARCHER, J.S. ET AL.: "Human growth hormone (hGH) secretion in milk of goats after direct transfer of the hGH gene into the mammary gland by using replication-defective retrovirus vectors" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA., vol. 91, no. 15, 19 July 1994, pages 6840-6844, XP002088503 WASHINGTON US cited in the application see page 6844, column 1, line 12 - line 14 ---	1,7-11
Y	---	1-11 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

Date of mailing of the international search report

18 December 1998

13/01/1999

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Chambonnet, F

INTERNATIONAL SEARCH REPORT

International Application No
PCT/CA 98/00607

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>YANG, N.S. ET AL.: "Gene transfer into mammalian somatic cells <i>in vivo</i>" CRITICAL REVIEWS IN BIOTECHNOLOGY, vol. 12, no. 4, 1992, pages 335-356, XP002088504 see page 338, column 2 see page 341, paragraph 3.</p> <p>---</p>	1-11
A	<p>WO 96 22379 A (NEXIA BIOTECHNOLOGIES INC) 25 July 1996 see page 24, line 8 - line 11; claims</p> <p>---</p>	5,7-9,16
A	<p>US 5 215 904 A (GOULD & WANG) 1 June 1993 cited in the application see the whole document</p> <p>---</p>	1
Y	<p>CULVER, K.W. ET AL.: "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors" SCIENCE., vol. 256, 12 June 1992, pages 1550-1552, XP002088505 LANCASTER, PA US see the whole document</p> <p>---</p>	1-11
Y	<p>WO 95 15167 A (GENETIC THERAPY INC) 8 June 1995 see the whole document</p> <p>---</p>	1-11

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 98/00607

Patent document cited in search report	Publication date	Patent family member(s)			Publication date
WO 9622379	A 25-07-1996	US 5780009	A 14-07-1998		
		AU 4428496	A 07-08-1996		
		CA 2210897	A 25-07-1996		
		EP 0805869	A 12-11-1997		
US 5215904	A 01-06-1993	NONE			
WO 9515167	A 08-06-1995	CA 2177998	A 08-06-1995		
		EP 0735887	A 09-10-1996		
		JP 9507839	T 12-08-1997		